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1.1. Ophthalmic drug delivery 
The human eye is a very unique and isolated organ containing the optical apparatus 
which is essential for vision (Fig. 1 [1]). The lens divides it into the anterior and 
posterior segment. The anterior segment consists of cornea, aqueous humor and iris 
ciliary body and the posterior part contains the retina and the vitreous body. Due to 
the missing blood vessels within the cornea, lens and vitreous body, the delivery of 
oxygen and nutrients is via diffusion in the aqueous humor. The eye can further be 
divided into three main layers; an outer fibrous layer (sclera and cornea), a middle 
vascular layer (choroid, ciliary body and iris) and an inner nervous layer (retina) [2]. 
 
Fig. 1: Horizontal section through the eye [1] 
There are various diseases affecting the eye. Examples are blepharitis, allergic, 
bacterial or viral conjunctivitis, keratitis, or dry eye syndrome at the anterior eye. 
Furthermore, there are proliferative vitreoretinopathy, retinitis pigmentosa or macular 
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degeneration at the posterior segment leading to severe patient discomfort [1]. For 
an efficient treatment drugs can be applied via different routes; topical, intravitreal, 
scleral or systemic. The topical administration is the most common route for diseases 
affecting the anterior eye, however, due to a high drug loss in the precorneal area, it 
is poorly suitable for treatment of complications in the posterior part [3]. To reach this 
section, intravitreal or sclera injections are preferred, even if they are associated with 
a high risk of complications [4]. After systemic application therapeutic drug levels can 
be reached in ophthalmic tissue, however, only 1 – 2 % of the plasma concentration 
is achieved and hence, toxic systemic concentrations can easily be reached and side 
effects may occur [3]. 
In the last two decades the main focus of ocular therapy was set in two arms. On the 
one hand, there was research for new effective drugs for the treatment of poorly 
controlled diseases, on the other hand, the improvement of ocular dosage forms for 
already existing drugs became a major issue [1].  
The most common approach for the administration of ophthalmic drugs is the delivery 
through simple aqueous eye drops. However, due to the physiological ocular 
barriers, those come with important disadvantages in terms of biocompatibility, 
bioavailability and toxicity [4, 5]. There are several barriers that hamper the corneal 
or scleral uptake of drug upon instillation. With the basal tear flow and the 
nasolacrimal drainage, which are usually responsible for the clearance of foreign 
particles from the eye surface, more than 95 % of the applied drug is directly washed 
out [3]. Furthermore, the amount of drug which is then unavailable at the eye surface 
may easily become systemically available and cause toxic effects, as for example 
known for the potent drug timolol after topical administration [6,7]. The cornea itself 
consists of different hydrophilic and lipophilic layers and thus causes difficult 
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conditions for its permeation by drugs. The final drug levels in corneal tissue and the 
bioavailability are discussed to be smaller than 1 – 5 % of the initially instilled drug 
dosing [8–10]. Another example of an ocular barrier in terms of drug resorption is the 
ocular – blood barrier [11]. It prevents the targeting of the posterior section of the eye 
through topical administration by stopping the travelling of drugs from scleral tissue 
over the retinal capillaries [11]. 
Thus, in recent years much effort was put in research to develop novel ophthalmic 
application systems to reach a higher bioavailability in combination with minimal to no 
further systemic side effects of potent drugs, the need of which increases steadily for 
prevalent diseases like dry eye disease. One approach was the preparation of in-situ 
gelling systems, which showed an increase in viscosity upon instillation and therefore 
prolonged the residence time of drug at the ocular surface [2]. Besides these, 
microemulsions, microsuspensions or colloidal systems like liposomes, 
nanoemulsions or nanoparticles were developed [2]. A benefit of these formulations 
was the possibility to incorporate higher levels of hydrophobic drugs compared to 
aqueous systems [2]. By choice of suitable surface characteristics of these systems it 
was possible to gather muscoadhesive properties, for example by charge, and thus 
to slow down the time of evaporation and to increase the bioavailability of the drug. 
Fialho et al showed a microemulsion system for 0.1 % of dexamethasone with double 
of the maximum drug absorbance, a faster penetration through the corneal layers 
and with twice the area under the curve as known for comparable conventional 
systems [12]. However, up to now it is not clear, if for example positively charged 
surfaces may not lead to toxic effects when applied over longer period [13, 14]. A 
different strategy is followed by the preparation of ocular inserts or minitablets. These 
systems are inserted in the conjunctival cul de sac and show tremendous potential to 
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increase the bioavailability by prolonged contact time and sustained drug release and 
furthermore to reduce side effects and the frequency of application. However, they 
show a lot of disadvantages like foreign body sensation, discomfort, a difficult 
handling or blurred vision which finally leads to discontinuation in therapy [15–17]. 
Nanosuspensions combine benefits of aqueous and solid systems by dispersion of 
drug nanoparticles in an aqueous environment. Due to the submicron size of their 
particles (200 – 600 nm), they improve the saturation solubility of the drug and 
hence, its bioavailability. Furthermore, they are also as functional as sustained 
release systems, which is a big step towards the safety and efficiency of drugs. 
Unfortunately, to prepare the particles, nanosuspensions suffer from a cumbersome 
manufacturing using preparation methods like for example the solvent displacement 
method or the ionic gelation technique or milling [18]. 
Besides all benefits which were gathered by the various novel formulation 
approaches, their compositions and manufacturing are far from simplicity and 
biocompatibility. Therefore, there is still a huge need for formulations which combine 
simplistic production and biocompatibility with enhanced drug solubility and an 
increase in bioavailability to have efficient tools for the treatment of the various 
ophthalmic diseases. 
1.2. Dry eye disease 
Dry eye disease (DED) is a severe medical problem with billions of people affected, 
and thus, a highly important issue for research. Over the last twelve years the 
number of publications has nearly increased by a factor of 6 (Fig. 2) [19].  
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Fig. 2: Trend in number of publications for the key words “dry eye” listed by SciFinder® between 2000 
and 2012 [20]; 
Due to current knowledge from research on hyperosmolarity and ocular surface 
inflammation in dry eye and the effect of dry eye on visual function, the definition of 
DED was re-defined by the International Dry Eye Workshop in 2007 as “… a 
multifactorial disease of the tears and ocular surface that results in symptoms of 
discomfort, visual disturbance, and tear film instability with potential damage to the 
ocular surface. It is accompanied by increased osmolarity of the tear film and 
inflammation of the ocular surface [21].” 
DED affects the lacrimal functional unit (LFU), which is the lacrimal glands, the ocular 
surface (cornea, conjunctiva, meibomian glands), the lids and the sensory and 
motory nerves connected to them. The overall function of the LFU is to preserve the 
tear film, the transparency of the cornea and the quality of the image projected onto 
the retina [22]. Diseases or damage of any of its components can destabilize the tear 
film and lead to DED. 
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The vicious circle of DED sketched by the International Dry Eye Workshop is shown 
in Fig. 3 [21]. Its core mechanisms, which initiate, amplify and potentially change its 
character, are tear hyperosmolarity and tear film instability. 
 
Fig. 3: Vicious circle of the multifactorial disease dry eye syndrome according to the International Dry 
eye Workshop 2007; core mechanisms (tear hyperosmolarity and tearfilm instability), inflammatory 
process and exogenous amplifying factors; [21] 
Hyperosmolarity of the tearliquid is the central mechanism causing ocular surface 
inflammation and damage. It typically arises via evaporation of water of epithelial 
surface cells and stimulates a cascade of inflammatory events (MAP kinases and 
NFκB signaling pathways) and the generation of inflammatory cytokines (IL-1α; IL-
1β), tumor necrosis factor (TNF) α and matrix metalloproteinases (MMP-9)[23,24], 
which directly leads to apoptotic cell death of epithelial cells like mucin secreting 
goblet cells [25].  
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Unrelated to prior tear hyperosmolarity, in some forms tear film instability is the 
indicating event of DED, such as after LASIK surgery or disturbances of the ocular 
surface mucins like xerophthalmia or allergic eye disease [21]. 
As a result of different epidemiologic studies on dry eye the consistent risk factors 
are for example age, gender with higher prevalence in women, postmenopausal 
estrogen therapy, low omega 3 and omega 6 fatty acid uptake or an antihistamine 
medication. The prevalence of DED in these studies varies dependent on the study 
criteria and the investigated group between 5.2 % and 63 % [26]. About 4.9 million 
Americans with an age over 50 suffer from DED and tens of millions have less 
severe but related syndromes [27]. The incidence of DED increased between 1990 
and 1998 at 57.4 %. In comparison cataract increased at 16.4 %. Regarding to the 
US-Census Bureau until 2050 the population between 65 and 84 years will increase 
at 100 % and the 85 years and elder ones at even 333 % [28]. Thus, this will further 
increase the incidence of DED. 
Dry eye patients often report symptoms like distinct pain, irritation, foreign body 
sensation, grittiness, excess tearing or in more severe case a decrease of their visual 
ability. Untreated, clinical course may proceed up to infection, corneal ulcer or even 
blindness [14]. Hence, DED is a tremendous problem concerning the patients’ quality 
of life. About 60 % of the patients feel hindered in their everyday life and even 37.5 % 
report to be less efficient at work in consequence of their affection [26, 29]. 
Upon these facts, regarding the prevalence, the incidence and also the adverse 
affects the patients have to deal with, there is a huge need for an efficient therapy. In 
general, the therapeutic options are twofold; palliative therapy and causal treatment. 
The main part of DED therapy is still palliative, what means that the disease is 
treated symptomatically. Several possibilities are reported, such as tear 
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supplementation, tear retention or tear stimulation by use of for example pilocarpine 
[30]. Tear retention using punctum plugs to retard the tear clearance and gather a 
more efficient treatment with eye drops is an option first reported in 1975 by Freeman 
et al. [31]. However, the most common treatment is tear supplementation to lubricate 
the eye, replace missing tear fluid, reduce the elevated tear osmolarity, wash out 
inflammatory agents and especially improve the patient comfort and the quality of life 
[32].  
Despite the symptomatic improvements using palliative therapeutics, the 
inflammation, which is part of nearly each form of DED stays untreated. Therefore, 
an anti-inflammatory therapy is more and more proclaimed [26]. Various options have 
been investigated like treatment with 15(S)-hydroxyeicosatetraenoic-acid, local 
androgens, corticosteroids or tetracyclines. However, cyclosporin A was finally found 
to be the most promising option in terms of a causal treatment. Unfortunately, until 
today there is just one formulation approved by the US Food and Drug Administration 
(FDA) for the treatment of DED in the US only [26,32]. 
Thus, as a result of the course of the disease and the current therapeutic options 
there is a tremendous lack of drug products using potent drugs like, for example, 
cyclosporin A which would be efficient in causal treatment of dry eye disease and 
would lead to a significant increase of the patients’ quality of life. 
1.3. Cyclosporin A: a potent but poorly soluble drug 
The cyclic undecapeptide cyclosporin A (CsA) is produced by Tolypocladium 
inflattum Gams and other fungi imperfecti [33]. It is successfully used as an oral 
immunosuppressant drug in transplantation medicine since the 1970s when it was 
discovered in the labs of Sandoz in Switzerland. Cyclosporin A binds to the 
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immunophilin cyclophilin and this complex inhibits the dephosphorylation of 
transcription factors especially the nuclear factor of activated T-lymphocytes (NFAT) 
and its subsequent translocation from the cytoplasm to the nucleus in an IL-2 
mediated process. Thereby the activation of promoters of the T-cell activation and 
the immune response are inhibited [34].  
Besides its use after graft surgery, it was shown for cyclosporin A, that it can reach 
ocular tissue via intravenous or oral administrations. It is effective in treatment of 
inflammations affecting the posterior segment of the eye as well as, for example, in 
peripheral ulcerative keratitis, severe Grave’s ophthalmopathy, autoimmune uveitis, 
atopic keratoconjunctivitis or dry eye disease [33]. In treatment of dry eye disease the 
mechanism of increasing the tear production is not completely unraveled, but it 
seems to be related to the immunomodulatory activity of cyclosporin A, which 
decreases the local inflammation [35]. However, to gather sufficiently high local 
tissue levels, high systemic concentrations have to be applied [33,36]. Unfortunately, 
if exceeding therapeutic levels, CsA may cause severe side effects like especially 
acute or chronic nephrotoxicity. Further toxic effects are hypertension, 
hyperlipidemia, gingival hyperplasia, neurotoxicity or thrombotic microangiopathy 
[37]. 
To overcome these severe problems, a local therapy of ophthalmic diseases would 
be preferential because much less CsA would transit into the blood stream. 
Furthermore, in DED this would mean a direct targeting of the site of disease. As 
patients, who received systemic CsA as standard therapy after transplantation, 
showed an increased tear production, a first study on topical CsA as a therapy for dry 
eye was conducted in 1994. Gunduz et al showed a significantly prolonged tear film 
break up time (TFBUT) and a decrease in rose Bengal staining. However, after 2 
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months of treatment with a 2 % CsA olive oil eye drop solution no improvement in 
Schirmer-I-test was found compared to the vehicle [38]. In following years numerous 
studies proved the inflammatory background of dry eye disease and the potential 
efficiency of topical cyclosporin A administration [22,39–41]. In 2000, Sall et al 
conducted two multicenter, randomized studies with twice a day local instilled 0,05 % 
and 0,1 % CsA emulsions over 6 months on 877 patients who showed mild to severe 
DED. He could show significant improvements with the corneal staining test and the 
Schirmer-I-test. Therefore, he proved the efficiency and safety of the formulations 
and found further that the higher concentrated emulsion was not beneficial compared 
to the lower concentrated one [42]. Other studies were able to observe a decrease of 
proinflammatory cytokine levels (interleukin (IL) -6) [43]. Small et al. finally reported 
that under a long term twice a day local treatment with those emulsions no relevant 
CsA levels were detected in blood [44]. Besides all these objective improvements 
gathered by first local treatments with CsA, it was not less important that patients 
reported to be more satisfied by this kind of therapy and had to use less tear 
substitutes [45]. 
However, in contrast to these first and promising results, further research on novel 
formulations has been hampered by severe hurdles. Unfortunately, cyclosporin A 
suffers from high lipophilicity (log P = 3.0 [46]) and with 6,6 µg/ml an extremely poor 
solubility in water [47] and thereby, cannot be administered via common ophthalmic 
formulations like aqueous eye drops. Thus, in the past in most studies CsA was 
administered dissolved in vegetable oils or emulsions, also containing an oil phase 
[42,48,49]. However, due to a high affinity of the lipophilic drug to the oil vehicle, the 
bioavailability of drug in corneal tissue was quite low [46]. Furthermore, oily vehicles 
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are poorly tolerated at the eye. Patients report burning, stinging and foreign body 
sensation after treatment with such systems [36,50].  
Therefore, a lot of research was conducted in recent years to fit the requirements of a 
ideal topical ophthalmic formulation. Such a perfect system should be well tolerated, 
easy in manufacturing and administration; it should prolong the drug residence time 
at the eye, have a long shelf life and finally avoid the systemic absorption [33]. 
Cyclodextrins, micellar systems, emulsions, liposomes and also nanoparticular 
systems were investigated. Promising results such as high drug loading in 
conjugation with an increased solubility, prolonged residence time and especially 
high corneal tissue levels were reported [20,51–55]. Unfortunately, many of these 
recently developed systems suffer from cumbersome manufacturing protocols or 
unclear biocompatibility [13,14,54,55]. 
Thus, there is still an immense need for formulations which are able to combine a 
high drug load with good biocompatibility and good bioavailability. 
1.4. Goals of the thesis 
This thesis is focused on the development of innovative liquid application systems for 
the poorly water soluble drugs cyclosporin A, budesonide and beclometasone for 
ophthalmic use. One of these formulations is an in-situ nanosuspension (INS). An 
INS is a clear and colorless solution consisting of drug, a non aqueous water miscible 
solvent, a surfactant and an amount of water that does not induce precipitation of the 
drug. Upon application and contact with the aqueous tear fluid the drug precipitates 
in the form of nanoparticles and is taken up by tissue (Fig. 4). A second approach for 
drug administration is the design of a self- assembling micellar formulation with 
special focus on a simplistic manufacturing and high biocompatibility. For the 
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development of such systems it was necessary to gather detailed information on the 
characteristics of solvents, additives and the drugs and especially on their 
interactions in terms of a controlled precipitation on the one hand and drug 
solubilization on the other hand. The challenge was to optimize such systems 
concerning simplicity, stability, biocompatibility and bioavailability in-vitro as well as 
in-vivo. 
 
Fig. 4: A poorly soluble drug, a surface active additive and the maximum possible amount of water that 
doesn’t induce a precipitation are solved in a non aqueous, but water miscible solvent to generate a 
clear solution by gentle stirring. In combination with the tear fluid, the administered droplet exceeds 
the critical water- content and with that the point of precipitation. The drug spontaneously precipitates 
into nanoparticles and is taken up by the tissue. 
First, the field of possible solvents and additives was investigated to limit the options 
for the formulation process to few promising compounds (Chapter 2) to find the 
optimal parameters for the development of an INS. To this end, poly(ethylene glycol) 
– based solvents were researched in terms of their qualities to solubilize lipophilic 
drugs and additives. They were furthermore physicochemically characterized and 
their compatibility with polymers occurring usually for manufacturing, primary 
packaging or filter membranes was tested. Finally, a turbidimetric high throughput 
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(tHTP) analytical method was developed and installed to obtain detailed information 
on the precipitation behavior of the drugs upon contact with water. 
In detailed tHTP studies, a defined composition of a cyclosporin A containing INS 
was designed (Chapter 3). As size and charge are highly important parameters for 
an ophthalmic formulation of nanoparticles [14,18,20], the nanoparticles resulting 
from the INS were characterized in these regards. Moreover, a first stability study 
was conducted. As information on biocompatibility of a formulation and further on the 
bioavailability of the applied drug are essential, to this end, analytical models, 
methods and equipment for the in-vitro studies on tolerability towards primary human 
epithelial cornea cells (HCEpiC) and drug resorption at enucleated porcine eyes were 
developed and described. 
In Chapter 4 a second approach for the administration of poorly soluble drugs at the 
anterior eye was described for a self- assembling micellar system with simple 
manufacturing. In a first study, suitable non-ionic surfactants were characterized and 
selected towards the development of preclinical formulations. According to the INS, 
the biocompatibility of these micellar solutions was proven at HCEpiC cells. Finally, 
their efficiency in terms of drug delivery into corneal tissue was investigated with the 
established porcine cornea model. 
As it is known from literature that surfactant micellar systems may be less stable than 
polymeric micelles [56,57], a long- term stability study was conducted to show to the 
stability and efficiency of the simplistic formulation (Chapter 5). 
Upon the information on biocompatibility and bioavailability, gathered by former in-
vitro studies, in the final study (Chapter 6), both formulations, the INS and the 
micellar solution were tested in-vivo on male rabbits to complete the set of pre-
1.4. Goals of the thesis 
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clinical data. Their biocompatibility was investigated for placebo and drug- loaded 
preparations and the drug cornea levels reached for the drug- loaded samples were 
analyzed thereafter by the established analytical setup and methods.
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Abstract 
For the delivery of poorly soluble drugs and especially for novel ophthalmic 
application systems like an in-situ nanosuspension (INS), where the drug should 
precipitate upon contact with water, there is a high demand of suitable solvents. 
Therefore, in the present study we investigated the properties and suitability of 
different liquid poly(ethylene glycols) (PEG) and ether derivatives thereof. All solvents 
showed excellent drug solubilizing qualities, in which the dimethyl ether PEGs (DME) 
dissolved the highest concentrations of the observed drugs budesonide, 
beclometasone and cyclosporin A (CsA). Among the additives only Solutol HS15, a 
non ionic surfactant, produced perfectly clear and liquid solutions in all solvents. The 
lowest viscosity was observed for DME500. Due to their negligible amounts of water, 
all solvents, as obtained from the manufacturer, were generally suitable for an INS. 
Furthermore, they showed resistance towards different plastics used with primary 
packing materials or syringes. Especially for regenerated cellulose (RC), used as 
filter membrane, a good wetting as well as no drug adsorption during filtration was 
observed. By use of a turbidimetric high throughput screening and light microscopy, 
the INS concept and its dependency of the used drug and solvent could be proven. 
Unfortunately, a modulation or controlling of the precipitation with Solutol was not 
possible.  
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2.1. Introduction 
The choice of suitable solvents or solvents for pharmaceutical applications has a 
tremendous impact on highly important parameters like biocompatibility, toxicity and, 
if a drug is present, also on resorption kinetics and, therefore, bioavailability [1,2]. 
Drugs with a poor solubility in water, like cyclosporin A (CsA), are often formulated 
with oily or organic excipients [3–5]. Unfortunately, irritations and low bioavailability 
are typical problems, especially after topical administration of such carriers [6]. 
Hence, on the one hand, new strategies and on the other hand, different kinds of 
solvents have to be investigated to enhance the efficiency of the applied drugs, and 
to keep patient compliance. 
For topical and ophthalmic administration, various types of poly(ethylene glycols) 
(PEG) are known from literature. PEG and its derivatives, such as ethers or fatty acid 
esters, offer great properties like very good biocompatibility and water solubility. They 
show no immunogenicity, no reproductive-, developmental- or genotoxicity and also 
no carcinogenic properties. Beneficial features of this class of substances are 
moderate to no ocular or dermal irritations and an extremely low acute and chronic 
toxicity [7,8]. PEG400, for example, is found as plasticizer in ocular inserts. PEGs are 
also an ingredient in lubricant eye drops for the treatment of dry eye disease (DED) 
like in Systane® Ultra (Alcon Laboratories) [9,10]. Bain et al used an amount of 10 % 
PEG to decrease the gelation temperature of methyl cellulose to create an in-situ 
gelling system with prolonged retention time at the anterior eye [11]. The methyl 
ether derivative (MPEG) is found as a part of co-polymers like MPEG-hexyl-
substituted polylactide which was used to solubilize CsA in polymeric micelles [8]. 
Due to their excellent transparency, a completely different approach was followed by 
Brandl et al, who used PEG based hydrogels as biodegradable intra-ocular drug 
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delivery systems [12]. Furthermore, Lennikov et al used liquid PEG to dissolve 
Astaxantin and investigated its UV protective properties towards the eye surface of 
mice in-vivo [13]. 
Based on this rich body of applications described for PEG, we decided to develop a 
novel kind of liquid, aqueous formulation using the advantages of PEG to overcome 
solubility barriers for hydrophobic drugs. Our intention was to overcome the use of 
oily vehicles and to enhance the presence of the instilled drug at the anterior eye. 
Our approach was to make use of the solubilizing qualities of PEG, to dissolve poorly 
water soluble drugs and then incorporate water up to a critical amount, where the 
solution is still “stable”. If such a system gets into contact with water, like for example 
after application at the eye with the tear fluid, a spontaneous precipitation of drug 
would be induced. In the present work, we investigated the suitability of different 
liquid poly(ethylene glycols) towards such an in-situ precipitating system for the 
lipophilic model drugs budesonide, beclometasone and cyclosporin A. 
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2.2. Materials and methods 
2.2.1. Materials 
Cyclosporin A (CsA), budesonide and beclometasone were supplied by the Pharma 
Stulln GmbH (Stulln, Germany). Solutol® HS 15, Soluplus®, Methocel® E15, 
Kollidon® 17PF and Kollidon® 12PF were a kind gift from the BASF (Ludwigshafen, 
Germany). Polyglycol 400 a poly(ethylene glycol) (PEG) (MW = 400 g/mol), Polyglycol 
M250, M350 and M500, three mono-methoxy-PEGs (MW = 250 g/mol, 350 g/mol, 
500 g/mol) and Polyglycol DME250 and  DME500, two dimethoxy-PEGs 
(MW = 250 g/mol and 500 g/mol), were supplied by Clariant Produkte GmbH 
(Frankfurt a. M., Germany). Deionized water was obtained from a Milli-Q water 
purification system from Millipore (Schwalbach, Germany). MeOH and MeCN (both 
HPLC grade) were purchased from Merck (Darmstadt, Germany).  
2.2.2. Solubility assessment of drugs 
500 mg of drug, budesonide, beclometasone and cyclosporin A were each dissolved 
in 1 ml of the solvents PEG400, M250, M350 and DME250. The samples were gently 
stirred for 24 hours at room temperature to make sure that the solutions were truly 
saturated with a sediment of drug still present. After centrifugation at 16.000 g for 
15 min, 100 µl of each sample were diluted with 900 µl of MeOH. 100 µl of the 
already diluted CsA samples were diluted once more with 900 µl of MeOH for 
analysis. 
The quantitative analysis of the residual drug content was carried out using high 
pressure liquid chromatography (HPLC). For each drug, a stock solution (SL) with a 
concentration of 5 mg/ml was prepared in MeOH. The SLs were diluted to 
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concentrations of 5, 1, 0.5, 0.1, 0.05 and 0.01 mg/ml with MeOH. The external 
standards were stored at -80°C until further analysis.  
HPLC analytics of budesonide: The Shimadzu chromatographic equipment 
(Shimadzu Deutschland GmbH, Duisburg, Germany) consisted of a SCL-10AVP 
controller and a LC-10ATVP pump that operated with a flow rate of 1 ml/min. Further, 
a SIL-10ADVP auto injector with a sample volume of 10 µl, a CTO-10ASVP oven with a 
temperature of 22 °C and the UV detector SPD-10AVP at a wavelength of λ = 244 nm. 
As solid phase a reversed phase octadecyl column Luna 3µ C18(2) 100A with 
100 x 4.6 mm was used (Phenomenex Ltd., Aschaffenburg, Germany). Isocratic 
elution was carried out with the methanol – water mixture (80:20, v/v) over 5 min.  
HPLC analytics of beclometasone: Chromatographic conditions were in general as 
described for budesonide using slightly different parameters. The flow rate was set to 
1,5 ml/min, the oven temperature was kept at 30 °C and UV detection was carried 
out at 238 nm. An isocratic elution was conducted with the MeCN – H2O mixture 
(60:40, v/v) over 10 min. 
HPLC analytics of cyclosporin A:  Chromatographic conditions were again as 
described for budesonide with slightly different parameters. The flow was set to 
1.0 ml/min, the oven temperature was kept at 75 °C and UV detection was carried 
out at 210 nm. The injection volume was 15 µl. The mobile phase consisted of 75 % 
MeCN and 25 % H2O (v/v). A gradient over 5 min to 90 % MeCN and 10 % water 
was applied. After 12.5 min the column was again re-equilibrated to the initial 
conditions until the end of the run at 15 min. 
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2.2.3. Solubility of additives 
20 mg, 50 mg and 100 mg of the additives Methocel E15, Solutol HS15, Soluplus, 
Kollidon 17PF and Kollidon 12PF were dispersed in 1 ml of each solvent and stirred 
using a Variomag® Multipoint stirrer (2mag-USA, Daytona Beach, FL, USA) for 24h 
at room temperature in transparent glass vials. The mixtures were visually inspected 
in terms of transparency, homogeneity and eventual presence of particles or not 
dissolved material. 
2.2.4. Viscosity 
The temperature- dependent viscosity of the solvents was recorded using an 
AR 2000 rheometer (TA Instruments, Eschborn, Germany) equipped with a plate – 
cone steel geometry with an angle of 2° and a diameter of 60 mm. The co-solvent 
was casted on the bottom plate of the rheometer and the cone was lowered to a gap 
size of 1000 µm. The system was shielded by a solvent trap, to avoid evaporation or 
other influences of the environment. At a constant shear rate of 100 s-1 the 
temperature ramp from 4 to 40 °C over a period of 20 min was started and viscosity 
was recorded. The measurements were performed in triplicate. 
2.2.5. Water- content of PEG 
The water- content of the solvents as contracted from the manufacturer was 
determined using Karl Fischer titration. Measurements were performed using a 
Moisturemeter MCI Model CA-02 (Mitsubishi Chemical Industries Limited, Tokyo, 
Japan). A 1 ml syringe was filled with sample and weighed. About one third of the 
syringe’s volume was injected into the reaction vessel and the mass of water was 
measured. The syringe with the remaining sample was weighed to determine the 
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injected mass. Measurements were performed in triplicate for each liquid. Afterwards 
the water- content was calculated as 
𝑥  %  (𝑤/𝑤)   =   !!!!!! ∙ 100, 
where 𝑥  %  (𝑤/𝑤)   is the water- content, 𝑚!!! is the measured mass of water and 𝑚! 
is the mass of the injected sample. 
2.2.6. Plastics resistance towards the solvents 
Discs of about 1x1 cm were cut out of polypropylene (PP), polyamide (PA) and 
celluloseacetate (CA) bars (Probesammlung zur Kunststoffkunde, Verband 
Kunststofferzeugende Industrie e.V., Frankfurt a.M.). A filter membrane made of 
regenerated cellulose (RC) was excised of a SpartanTM 13 mm syringe filter (pore 
size = 0.2 µm) (Whatman GmbH, Dassel, Germany). The samples were transferred 
in glass vials and covered with 5 ml of PEG400, M250, M350 and DME250, 
respectively. Further, 4 BD DiscaditTM II syringes (Becton Dickinson GmbH, 
Heidelberg) of PP (tube) / poly ethylene (PE) (plunger) / oleamid (anti-blocking agent) 
were filled with the solvents. All samples were stored at room temperature under light 
exclusion for 15 days. They were examined visually every day in terms of 
transparency of the solution and transformation of the slices. At day 15, UV – spectra 
were taken of the pure solvents and the samples over a range from 190 to 900 nm 
using a UVIKON 941 double beam UV/VIS spectrophotometer (KONTRON 
Instruments, Neufarn, Germany) to detect the potential dissolution of the different 
polymers. The samples were prepared and measured in triplicate. 
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2.2.7. Contact angle measurements 
The contact angle of water and solvents (PEG400, M250, M350 and DME250) was 
measured on a RC filter membrane, excised of a SpartanTM 32mm syringe filter, 
using a Dataphysics contact angle system OCA 15 Plus (Dataphysics Instruments 
GmbH, Filderstadt, Germany). One droplet of sample was deposited on the 
membrane and the contact angle was recorded in triplicate. 
2.2.8. Drug adsorption on RC-filter membranes 
Solutions with a concentration of 1 mg/ml of drug in PEG400 were prepared with 
budesonide and CsA by gentle stirring. The transparent solutions were filtered 
through a SpartanTM 13mm syringe filter with a pore size of 0.2 µm. 100 µl of the non-
filtered solutions and the filtered solutions, respectively, were diluted with 900 µl 
MeOH in HPLC vials. The quantitative analysis was carried out by HPLC as 
described in 2.2.2. 
2.2.9. Turbidimetric high throughput screening 
The turbidimetric high throughput (tHTP) screening was performed to determine the 
critical water- content and hence, the solubility of budesonide and beclometasone in 
ternary as well as in quaternary systems (Tab. 2.1). The turbidity was measured at a 
single wavelength of λ = 550 nm using a Titertek Plus plate reader (ICN Biomedicals 
Ltd, High Wycombe, UK). All measurements were performed triplicate in a 96 well 
quartz microplate (Hellma, Müllheim, Germany). The initial sample volume was 50 µl 
per well. The first well in each row was a blank solution. The plate was alternately 
measured at λ = 550 nm, titrated with 2 µl water per well, gently vortexed at level 3 
using a Vortex-Genie®2 equipped with a 3-inch platform with rubber cover (Scientific 
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Industries, Inc., Bohemia, USA) and again measured at λ = 550 nm. This cycle was 
repeated until each well showed a precipitation. The absorbance of the increasing 
concentration of H2O (% (w/v)) was plotted against the drug concentration (% (w/v)). 
The point of precipitation (PoP) was defined as the concentration of water at which 
the absorbance starts to increase by at least 30 % with respect to the mean of the 
five previous absorbance values. 
2.2.9.1. Sample preparation for measurements in ternary systems  
(drug, solvent, water) 
The solvents PEG400, M250, M350 and DME250 were investigated with CsA and 
budesonide. In combination with budesonide additionally M500 and DME500 were 
investigated. With every solvent a colorless, transparent stock solution of 
10 mg/ml budesonide and 20 mg/ml beclometasone was produced by gentle stirring. 
The stock solutions were diluted with the appropriate solvent to concentrations of 1, 
0.75, 0.5, 0.25, 0.1 % budesonide (w/v) and 2.0, 1.5, 1.0, 0.5, 0.25, 0.1 % 
beclometasone (w/v) (Tab. 2.1).  
2.2.9.2. Sample preparation for measurements in quaternary systems  
(drug, solvent, surfactant, water) 
Solubility in quaternary systems was investigated for budesonide only (Tab. 2.1). 
Two different initial concentrations of the non-ionic surfactant Solutol were tested. 
Two stock solutions were produced: stock solution 1 (SL1) containing 2 % (w/v) 
budesonide, stock solution 2 (SL2) containing 40 % (w/v) Solutol and 10 % (w/v) 
Solutol, respectively. Stock solution 3 (SL3) with c(budesonide) = 1 % (w/v) and 
c(Solutol) = 20 % (w/v) and accordingly c(Solutol) = 5 % (w/v) was received by mixing 
1 ml SL1 with 1 ml SL2. SL4 was obtained by dissolving 200 mg/ml and 50 mg/ml 
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Solutol, respectively, in the different solvents. The SL3 was diluted with the 
corresponding SL4 to 5 concentrations of 1, 0.75, 0.5, 0.25, 0.1 % budesonide (w/v). 
Tab. 2.1: tHTP-screening; overview of the sample preparation and measurement cycle for the 
determination of the PoPs with budesonide (BUD) and beclometasone (BEC); left side: composition of 
all ternary systems; right side: composition of the quaternary systems; All concentrations are displayed 
(w/v); 
PEG400 M250 M350 M500 DME250 DME500 
      
ternary systems      
    quaternary systems 
    + Solutol  
    5% 20% 
+ BUD + BEC   + BUD + BEC 
1.00 % 2.0 %   1.00 % 1.00 % 
0.75 % 1.5 %   0.75 % 0.75 % 
0.50 % 1.0 %   0.50 % 0.50 % 
0.25 % 0.5 %   0.25 % 0.25 % 
0.10 % 0.25 %   0.10 % 0.10 % 
 0.10 %     
+ stepwise 2 µl H2O; vortexing; turbidimetric measurement at λ = 550 nm 
calculation of the PoPs 
 
2.2.10. Light microscopy of a budesonide precipitate 
A 0.5 % (w/v) budesonide solution in DME250 was prepared by gentle stirring. 400 µl 
of this solution were precipitated with 600 µl of H2O, to exceed the PoP. 15 µl of the 
dispersion were put on a glass slide and spread by adding a coverslip. Light 
microscopy pictures were taken using a Leica DM IRB microscope equipped with a 
PL Fluotar 10x (NA 0.3; PH 1) objective (Leica Microsystems Inc, Deerfield, IL, USA) 
and the EclipseNet Software (Laboratory Imaging, s.r.o., Praha, Czech Republic). 
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2.2.11. pH and osmotic pressure measurements of carrier mixtures 
Aqueous stock solutions of M500 and DME500 were prepared with concentrations of 
10 % and 20 % (w/v) for each solvent. The samples were prepared by addition of 0, 
5, 10 and 20 % (w/v) Solutol to each stock solution. pH was measured at room 
temperature under gentle stirring using a Sartorius PB-11 basic pH meter equipped 
with a pH combination electrode PY-P11 (Sartorius AG, Goettingen, Germany). The 
osmotic pressure was determined using a Knauer – semi micro osmometer K7400 
(KNAUER Wissenschaftliche Gerätebau Dr. Ing. Herbert Knauer GmbH, Berlin, 
Germany). 
2.2.12. Short term stability of budesonide and cyclosporin A 
Aqueous solutions of 85 % M500 and DME500, respectively, containing 0.1 % (w/v) 
budesonide and 1 % CsA, respectively, were prepared by gentle stirring. Due to a 
known lowered stability of CsA in the presence of ionic additives, like sodium chloride 
[14], or phosphate buffered systems (data not shown), the solutions were not 
buffered. The 1 ml samples were stored at 25°C and 65 % relative humidity. 
Budesonide samples were drawn at day 0, 2, 4, 8, 23, 36 and 43. CsA samples were 
taken at day 0, 1, 3, 5, 8, 15, 29 and 43. All samples were centrifuged at 16000 g for 
15 min. 100 µl of the supernatant were diluted with 900 µl of MeOH and stored at  
-80°C until further analysis. The quantitative analysis was carried out by HPLC as 
described in 2.2.2. All samples were prepared in triplicate. 
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2.3. Results and discussion 
2.3.1. Solubility of drugs 
As a first essential feature, the solubilizing capacities of the solvents PEG 400, M250, 
M350 and DME250 were investigated for the three poorly soluble drugs budesonide, 
beclometasone and cyclosporin A. The results are displayed in Fig. 2.1. All solvents 
showed excellent solubilizing properties. Budesonide which has a solubility in water 
of about 14 µg/ml [15] was dissolved in levels of at least 12.5 ± 0.6 mg/ml in M350 
and at a maximum of 21.8 ± 0.8 mg/ml in DME250, which is a 900 fold increase of 
the amounts in water. The dissolved beclometasone concentrations were between 
24.4 ± 4.3 mg/ml and 55.4 ± 6.5 mg/ml. In comparison, its solubility in water is 
approximately 2 µg/ml [16]. Cyclosporin A, with a solubility in water of 6.6 µg/ml [17], 
showed the highest solubility increase. There were at least 100 mg/ml soluble in 
PEG400 and up to 293.5 ± 9.3 mg/ml in DME250. Due to problems with the 
purification for the HPLC samples, the exact values for CsA in PEG400 could not be 
determined. In all experiments the solutions of a minimum of 100 µg/ml were 
perfectly transparent.  
The soluble concentrations of the three drugs exceed clearly the typically used 
amounts in various formulations like for example suspensions, ethanolic solutions or 
micreoemulsions [1,18–22]. Hence, due to their solubilizing qualities, all solvents 
seemed to be promising options for the INS. 
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Fig. 2.1: Solubility of (upper panel) Budesonide ( ), beclometasone ( ) and (lower panel) 
cyclosporin A ( ) in liquid poly(ethylene glycols) determined by HPLC; (n=3) 
2.3.2. Solubility of additives 
In order to modulate and control an INS in terms of particle growth and size following 
precipitation in water as well as their retention time at the site of application, such as 
the eye surface, additives like viscosity enhancers (VE), surfactants (AS) or other 
solubilizing agents (OS) were regarded as an option. Hence, the solubility of various 
additives in the solvents was investigated. The results of the screening are shown in 
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Tab. 2.2. With Methocel E15 a VE and Soluplus an AS only opaque dispersions were 
observed. Neither at low concentrations of 2 % nor at high concentrations of 10 % 
both substances could be dissolved. Both, Kollidon 12PF and 17PF, two OS, showed 
transparent and colorless solutions in all liquids despite the di-methylether derivatives 
DME250 and DME500. This may be due to their higher lipophilicity stemming from 
their methoxy groups. The only additive which showed perfectly clear solutions in all 
solvents was the non-ionic surfactant Solutol HS15. At all concentrations generated 
transparent mixtures were obtained. Due to its compatibility with all media, Solutol 
was used as a model additive for all further investigations. 
Tab. 2.2: Solubility of viscosity- and solubility-enhancing additives in different concentrations in the co-
solvents; (  = clear, transparent and colorless solution) 
 PEG400 M250 M350 M500 DME250 DME500 
c(add)/% 2 5 10 2 5 10 2 5 10 2 5 10 2 5 10 2 5 10 
Methocel 
E15 
                  
Solutol 
                  
Soluplus 
                  
Kollidon 
17PF 
                  
Kollidon 
12PF 
                  
 
2.3.3. Viscosity of the solvents 
The viscosity of the pure solvents was determined at temperatures from 4 to 40°C. 
The results and corresponding curves are displayed in Fig. 2.2. The solvents showed 
a temperature dependent decrease of the viscosity, which is typical for liquids, due to 
the lower molecular interactions at higher temperatures [23]. Only for DME500 a 
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nearly constant viscosity of around 10 mPa s was determined between 13 and 40 °C. 
Furthermore, the viscosity showed a decrease with declining molecular weight on the 
one hand, and with end-capping, on the other hand. Hence, for PEG400 the highest 
levels and for DME250 the lowest levels were observed. At a temperature below 
13 °C, M500 and DME500 showed a tremendous viscosity increase to levels higher 
than 16 Pa s at 4 °C. This increase is due to melting temperature of 12°C and 13°C 
for M500 and DME500, respectively, reported by the supplier for the two solvents 
with the highest molecular weight. Due to their lower melting point, the other solvents 
were less prone to viscosity changes when lowering the temperature to 4°C. At a 
temperature of 34°C, typical of the eye surface [24], the viscosity of all solvents was 
between 7 and 20 mPa s except for PEG400 which had a viscosity of 60 mPa s. As 
reported by Han et al, the ideal viscosity of lubricant eye drops for the treatment of 
dry eye disease is around 6 – 12 mPa s [25]. Thus, the pure solvents nearly were in 
this range, but there would still be options for the formulation process, especially 
because Han et al reported levels at room temperature, which were slightly higher. 
Values reported for PEG400 in the literature fitted the observed viscosity levels and 
proved the results [25]. Further, the data reported in the material safety data sheet of 
the supplier matched the results at the comparable temperatures. 
In conclusion, all the solvents showed good fluidity, but also enough viscosity to be 
able to be retained on the eye surface. Due to its obviously missing temperature 
dependency between 13 and 40°C but constantly increased viscosity, DME500 
showed very interesting features for an ophthalmic formulation. 
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Fig. 2.2: Viscosity as a function of temperature from 4°C to 40°C of liquid poly(ethylene glycols) 
PEG400, M250, M350, M500, DME250 and DME500; n = 3; 
2.3.4. Moisture of non-aqueous solvents 
As the INS preparation should precipitate spontaneously upon contact with water 
such as in the case of the aqueous tear fluid, it is of utmost importance to control the 
water- content of the formulations exactly. The water- content of the contracted 
solvents was determined by Karl-Fischer titration. All solvents showed only traces of 
water which decreased with end-capping and increasing chain length (Fig. 2.3). This 
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is in accordance with the results determined by Cohen et al. [26] who found a 
decreasing hygroscopicity for polyethylene glycols with an increasing molar weight.  
 
Fig. 2.3: Water- content of the different liquid polyethylene glycol co-solvents determined by Karl-
Fischer titration; 
The insignificantly low concentrations of water in the pure solvents were neglected 
for the further development of the INS. 
2.3.5. Compatibility of the solvents towards plastics and filter membranes 
In the process of production and packaging pharmaceuticals get into contact with 
many devices made of polymers. In order to prove the compatibility, we investigated 
the UV spectra of the solvents before and after incubation with polymers bottles, 
syringes or filter membranes are made of. The UV spectra are displayed in Fig. 2.4. 
The spectra after storage with packing materials like PP or PA as well as the spectra 
after storage in a PP / PE / oleamid syringe did not differ from the spectra of the pure 
solvents. Also the filter membrane built of RC did not cause a change of the solvent’s 
spectrum, no matter which solvent was used. Only the filter membrane made of 
cellulose acetate (CA) was dissolved by all solvents. An obvious opacity was 
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determined visually and all the spectra showed clear changes in comparison to the 
pure solvents and the other investigated plastics. These results fit the data in the 
literature. CA is known to be instable with solvents and RC is offered as a solvent- 
resistant alternate material [23].  
 
Fig. 2.4: Compatibility of the co-solvents with different plastics of possible filter membranes, primary 
packing materials or syringes proven by UV-spectra;  pure co-solvent,   RC,   CA,  PP,  
PA, PP/PE/oleamid syringe; n = 3; 
In order to investigate the suitability of RC as a filter membrane for sterile filtration, 
the contact angle as a measure for the wettability with the solvents was determined. 
The results are shown in Fig. 2.5 (A). Nearly similar angles between 20° and 35° at 
the RC surface were observed for all solvents and for water which was used as a 
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reference. Due to the fact that the observed angles were very low, we expected a 
quite good filterability from these results.  
 
Fig. 2.5: (A) Contact angle on a RC filter membrane of liquid poly(ethylene glycols); (n=3); (B) drug 
adsorption on a RC filter membrane;  budesonide,  cyclosporin A; (n=3); 
The RC membrane was further investigated in terms of drug adsorption. Solutions of 
1 mg/ml budesonide and cyclosporin A in PEG400 were analyzed by HPLC before 
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and after filtration. The data is displayed in Fig. 2.5 (B). As RC membranes are 
usually known to have low tendency towards drug adsorption and high recovery rates 
[27], the membrane accordingly showed a recovery of 100 % for CsA, as well for 
budesonide. From this data, it can be concluded that materials such as PP, PA or PE 
as well as filter membranes out of RC should be suitable for use in production or 
primary packing of the INS. 
2.3.6. Proof of the ‘in-situ Nanosuspension’ concept 
As the INS concept is based on a spontaneously induced, but defined drug 
precipitation upon contact with a physiological liquid like the tear fluid, the essential 
task was to investigate this precipitation in terms of its reproducibility, the 
dependency of different solvents, drugs and their concentrations. The PoPs, 
determined by a turbidimetric HTP screening, are shown in Fig. 2.6. 
As expected, the critical amounts of water increased with decreasing drug levels. 
PEG400, M250 and M350 thereby showed the lowest PoPs and their behavior was 
nearly identical over the whole range. With DME250, however, the PoPs were 
obviously higher. For 0.03 % beclometasone and 0,04 % budesonide, the critical 
amounts of water were up to 55.4 ± 0.7 % and 70.2 ± 0.0 %, respectively. Due to its 
higher critical amounts of water, budesonide was additionally investigated with M500 
and DME500 as solvents and with levels of 74.5 ± 0.1 % and 77.2 ± 0.2 % water the 
critical amounts of water were even higher than for DME250. In general, 
beclometasone clearly showed lower PoPs than budesonide, no matter which solvent 
was used. This may be due to the lower solubility of beclometasone in water, as 
mentioned in 2.3.1. Due to the fact as it was shown in preliminary experiments for 
CsA (data not shown), that surface active agents are suitable to change the 
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precipitation in terms of particle size and distribution, the influence of 5 % or 20 % 
Solutol on the critical water- content was investigated for budesonide.  
 
Fig. 2.6: Drug solubility and determination of the points of precipitation in ternary mixtures of drug, co-
solvent and H2O for beclometasone (upper panel) and budesonide (lower panel); PEG400 ( ), M250 (
), M350 ( ), M500 ( ), DME250 ( ), DME500( ); 
Because of their excellent behavior in the ternary systems, M500 and DME500 were 
chosen as solvents for these experiments in quaternary systems. Unfortunately, the 
tHTP screening in the quaternary systems of drug, solvent, surfactant and water 
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showed no further precipitation. The solutions stayed stable and formed most likely 
micellar structures that encapsulated the drugs.  
 
Fig. 2.7: Light microscopic picture of the precipitate of a 0.5 % budesonide in DME250 at 10fold 
magnification; scale bar 200 µm; 
Finally, to visualize the precipitated structures of the ternary systems, light 
microscopy pictures were taken. Fig. 2.7 shows the microscopic picture of a 0.5 % 
budesonide in DME500 precipitate as an example. The structures were “cloudy” and 
agglomerated. No individual, defined structures were detectable, as expected due to 
the missing stabilizing additive. In conclusion, the functionality of the basic concept of 
the INS could be proven for poorly soluble drugs. The small standard deviations of 
the precipitation experiments show that it was possible to precipitate the drugs 
reproducibly at defined critical water amounts. Furthermore, by use of suitable 
solvents, high levels of water could be incorporated until precipitation occurred which 
would be very beneficial in terms of physiological compatibility. Regrettably, the 
addition of Solutol in combination with budesonide had no further influence on the 
critical water amounts and on the precipitated particles and their size. It even 
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inhibited the whole precipitation. Therefore, to control an INS containing budesonide, 
efficient additives still have to be identified. 
2.3.7. Physicochemical characterization of INS carrier mixtures 
Placebo carriers of the INS containing additive (Solutol), solvent (M500 or DME500) 
and water were investigated in terms of osmotic pressure and pH, to estimate their 
physiological tolerance. The pH of all mixtures was in a range from 3,9 to 6,7 (Fig. 
2.8). It increased with increasing levels of Solutol. At higher solvent concentrations, 
for example 50 % or 80 % without Solutol, the pH was clearly higher.  
 
Fig. 2.8: Osmotic pressure (M500( ), DME500( )) and pH (M500( ), DME500( )) of different 
aqueous co-solvent - solubilizer combinations; 
The values were 6,8 and 8,4 (data not shown). Mixtures with DME500 showed 
clearly higher values than with M500. The osmotic pressure ranged from nearly 
isotonic solutions of 10 % solvent with 304 and 307 mosmol to clearly hypertonic 
   2.3. Results and discussion 
47 
 
solutions of 20 % solvent and 20 % Solutol with 2915 and 2895 mosmol for DME500 
and M500, respectively. In general, all mixtures were hypertonic. Levels of 
572 mosmol are reported to be usually tolerated at the anterior eye without side 
effects [28]. In addition, it was disclosed in the suppliers’ material safety data sheet 
(MSDS) that even the pure solvents showed no irritation at rabbits’ eyes (Method: 
OECD 405). 
As a result of the tHTP screening (2.3.6) an INS would have a level of 20 % or even 
more solvent. However, in terms of a formulation, it has to be proven in-vivo if the 
high osmolarities will be tolerated. 
2.3.8. Short term stability of budesonide and CsA 
In order to assess the compatibility of the solvents with the drug, the stability of 
budesonide and CsA was investigated with M500 and DME500 at increased solvent 
concentrations over a period of 43 days at room temperature. As shown in Fig. 2.9, 
the concentration of budesonide, dissolved in M500, starts to decrease with day 23 
down to less than 80 % of the initial concentration at day 36. Dissolved in DME500, 
the degradation starts right from the beginning down to less than 40 % of the initial 
concentration on day 36. It is reported in the literature for the stability of budesonide 
that the optimum pH range is 4 – 5. The more the pH reaches higher values, 
budesonide degrades rapidly [29]. The solutions had a pH of 6.7 and 8.5 for M500 
and DME500, respectively. That seemed to be one reason for the more rapid loss of 
budesonide with DME500. But also the pH in M500 was higher than the pH in the 
stability optimum of budesonide, which may be an explanation for the decrease after 
23 days. Due to this strong decrease, the measurements were stopped after 36 days 
for both solvents. The use of DME500 seemed not to be possible for INS in 
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combination with budesonide. With M500, a defined pH adjustment and further 
compatibility study need to be conducted to obtain stable formulations and exclude 
effects of the solvent itself on the degradation of the drug. 
 
Fig. 2.9: Drug stability of Budesonide (upper panel) and CsA (lower panel) in 85 % M500 ( ) and 
85 % DME500 ( ) over a period of 36 and 43 days; measurements were performed in triplicate; 
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The CsA solutions had a pH of 8.5 and 7 for DME500 and M500, respectively. A pH 
related instability as seen for budesonide was not expected. CsA showed stability 
over the whole period for both formulations. The residual amounts were above 90 % 
of the initial CsA concentration. Slightly higher levels of drug were detected in 
DME500. Due to its cyclic structure and lipophilic character, CsA is basically known 
to be very stable over a wide range of experimental conditions [30]. With a later 
formulation for the anterior eye in mind the solvents seemed not to be a limiting factor 
in terms of drug stability and their influence may even be less problematic based on 
the presumably lower concentrations used in the final formulations. 
2.4. Conclusion 
The investigated solvents showed many suitable characteristics, as for example a 
high solubilizing potential, low water- content and good compatibility with polymers. 
This makes them good candidates for the solvent component of an in-situ 
precipitating formulation for water insoluble, lipophilic drugs. We could show that the 
concept of an INS with defined points of precipitation worked. Unfortunately, a 
modulation or controlling of the precipitation to with additives like Solutol was not 
possible. Due to the hyperosmolarity of the solvents in higher concentrations, 
biocompatibility studies have to be conducted in-vitro and in-vivo. Even if there was a 
clear trend among the solvents, the detailed characteristics were very special for 
each system consisting of drug, solvent and water. Based on this data the INS has to 
be further investigated for cyclosporin A (Chapter 4). As in presence of Solutol no 
further precipitation could be induced, the option of clear aqueous formulations using 
non-ionic surfactants like Solutol should be observed as a second promising 
approach (Chapter 4). 
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Abstract 
With about 50-60 billion only in the US, dry eye disease (DED) is a severe medical 
problem. Even though there are potent drugs like cyclosporin A (CsA), due to their 
poor solubility in water, there is still huge lack in causal treatment. We developed an 
in-situ nanosuspension (INS) as a novel approach towards the administration of CsA 
at the anterior eye. The INS solution precipitates upon contact with the tear fluid and 
creates the active system right at the site of application in form of drug nanoparticles. 
Therefore we selected two suitable solvents (Polyglycol M500; Polyglycol DME500) 
out of different liquid poly(ethylene glycols). Aqueous solutions of these and a 
surfactant were well tolerated by primary human epithelial cells in vitro. To determine 
the critical water- content for a precipitation, the solubility of CsA was investigated in 
quaternary systems of drug, solvent, surfactant and water. Further, particle size and 
distribution were screened as a function of drug- and surfactant concentration. 
Finally, DME500 showed the best qualities as solvent for an INS and four different 
INS solutions were developed and characterized. The best solution showed a particle 
size of 505 ± 5 nm, a polydispersity index (PdI) of 0.23 ± 0.0 and a neutral zeta 
potential of -0.07 ± 0.05 mV. After single instillation at porcine eyes in-vitro, 
3345 ± 744 ngCsA/gcornea were detected in corneal tissue, while the levels of Restasis® 
with 545 ± 137 ngCsA/gcornea were significantly lower (P < 0.01). Upon these results, 
the INS proved our hypothesis and marked a promising, novel approach towards the 
causal treatment of inflammatory diseases at the anterior eye.  
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3.1. Introduction 
Many highly potent drugs for the therapy of ophthalmic diseases suffer from a poor 
solubility in aqueous media. Cyclosporin A (CsA), for example, is highly efficient in 
the treatment of inflammation affecting the anterior eye. CsA was successfully 
applied in vernal conjunctivitis [1], dry eye syndrome [2], corneal graft rejection after 
transplantation [3], uveitis [4], necrotizing scleritis [5], Sjogrens syndrome [6], 
Behcet’s disease [7] and thyroid ophthalmopathy [8].However, CsA has a high 
lipophilicity [9] and is with a solubility of 6.6 µg/ml practically insoluble in water [10]. 
Therefore, CsA has been administered in oily formulations [11–13] or ointments 
[14,15]. Unfortunately, such vehicles suffer from two major disadvantages. Since they 
come along with a burning sensation, an irritative effect on the cornea and blurred 
vision [16,17], patient compliance of such preparations is low. Furthermore, due to its 
higher affinity for an oily phase of a formulation compared to the aqueous milieu of 
the cornea [9], only small amounts of CsA become available in tissue [18]. To 
overcome this limitation high concentrations, commonly about 2.0 % of CsA must be 
applied to reach a therapeutic effect [19].  
Substantial effort has been devoted to research on colloidal formulations to 
overcome these problems. Besides an increased apparent solubility of drug in an 
aqueous environment, colloidal systems offer a number of options to deliver drugs 
into the cornea by processes such as adhesion to cells or penetration into the inter 
cellular space [20–24]. A variety of colloidal systems, like drug- loaded cyclodextrins 
[25], micelles [18,26], liposomes [27] or nanoparticles [28–30] have been considered 
as suitable carriers for CsA, but only a 0.05 % CsA castor oil based microemulsion 
(Restasis®, Allergan, USA), developed by Ding et. al [31] made it to the US market 
for the therapy of Keratoconjunctivitis sicca (KCS) to date [17,32]. However, 
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Restasis® shows typical side effects like burning and stinging sensation [33,34] and 
suffers from low tissue concentration levels [35]. 
We hypothesize that CsA nanocrystals could overcome this limitation and 
concomitantly avoid the typical side effects of oily components. To create such a 
nanosuspension in-situ could be an innovative approach since it would avoid the 
frequently cumbersome manufacture and handling of drug nanocrystals [36,37] and 
excel colloidal formulations in terms of bioavailability at the same time. We developed 
our in-situ nanosuspension system (ISN) such that CsA is dissolved in a 
solvent / water mixture from which the drug precipitates spontaneously in 
nanoparticular structures upon contact with the tear fluid. 
 In this study we describe the development of an INS for CsA and the availability of 
drug in excised porcine cornea.  
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3.2. Materials and methods 
3.2.1. Materials 
Cyclosporin A (CsA) and BLUyal® UD an aqueous 0.15 % sodium hyaluronate 
solution were supplied by the Pharma Stulln GmbH (Stulln, Germany). Cyclosporin D 
(CsD) was a kind gift of Prof. Dr. F. Kees (University of Regensburg, Regensburg). 
Solutol® HS 15 was a kind gift from the BASF (Ludwigshafen, Germany). Polyglycol 
400 a poly(ethylene glycol) (PEG) (MW = 400 g/mol), Polyglycol M250, M350 and 
M500, three methoxy-PEGs (MW = 250 g/mol, 350 g/mol, 500 g/mol) and Polyglycol 
DME250 and  DME500, two dimethoxy-PEGs (MW = 250 g/mol and 500 g/mol), were 
supplied by Clariant Produkte GmbH (Frankfurt a. M., Germany). Deionized water 
was obtained from a Milli-Q	   water purification system from Millipore (Schwalbach, 
Germany). Primary human cornea epithelial cells (HCEpiC) and corneal epithelial cell 
medium (CEpiCM) were purchased from Sciencell Research Laboratories (Carlsbad, 
USA). Methanol and acetonitrile (both HPLC grade) were purchased from Merck 
(Darmstadt, Germany). 0.1 N hydrochloric acid was obtained from Carl Roth 
(Karlsruhe, Germany). 
3.2.2. Turbidimetric precipitation survey 
3.2.2.1. Sample preparation for measurements in ternary systems  
(drug, solvent, water) 
The six non-aqueous solvents were investigated. With every solvent a colorless, 
transparent stock solution of CsA (10 % (w/v)) was produced by gentle stirring. The 
stock solutions were diluted with the appropriate solvent to nine different 
concentrations of 10, 8, 6, 4, 2, 1, 0.5, 0.25 and 0.1 % CsA (w/v) (Tab. 3.1).  
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3.2.2.2. Sample preparation for measurements in quaternary systems  
(drug, solvent, surfactant, water) 
Solubility in quaternary systems was investigated with M500 and DME500, 
respectively. Two different initial concentrations of the non-ionic surfactant Solutol 
were tested. Two stock solutions were produced: stock solution 1 (SL1) containing 
6 % (w/v) CsA, stock solution 2 (SL2) containing 40 % (w/v) Solutol and 10 % (w/v) 
Solutol, respectively. Stock solution 3 (SL3) with c(CsA) = 3 % (w/v) and 
c(Solutol) = 20 % (w/v) and accordingly c(Solutol) = 5 % (w/v) was received by mixing 
1 ml SL1 with 1 ml SL2. SL4 was obtained by dissolving 200 mg/ml Solutol in the 
different solvents. The SL3 was diluted with the SL4 to 5 different concentrations of 3, 
2, 1, 0.5, and 0.1 % CsA (w/v) (Tab. 3.1). 
3.2.2.3. Turbidimetric measurement cycle 
The turbidimetric high throughput (tHTP) screening was performed to determine the 
solubility of CsA in ternary, as well as in quaternary systems. The turbidity was 
measured at a single wavelength of λ = 550 nm using a Titertek Plus plate reader 
(ICN Biomedicals Ltd, High Wycombe, UK). All measurements were performed in 
triplicate in a 96 well quartz microplate (Hellma, Müllheim, Germany). The initial 
sample volume was 50 µl per well. The first well in each row was a blank solution. 
The plate was alternately measured at λ = 550 nm, titrated with 2 µl H2O per well, 
gently vortexed at level 3 using a Vortex-Genie®2 equipped with a 3-inch platform 
with rubber cover (Scientific Industries, Inc., Bohemia, USA) and again measured at 
λ = 550 nm. This cycle was repeated until each well showed a precipitation. The 
absorbance of the increasing concentration of H2O (% (m/m)) was plotted against 
the c (CsA) (% (m/m)). The point of precipitation (PoP) was defined as the water 
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concentration the absorbance started to increase with at least 30 % with respect to 
the mean of the five previous absorbance values. 
Tab. 3.1: tHTP-screening; schematic overview of the sample preparation and the measurement cycle 
for the determination of the PoPs; left side: composition of the ternary systems; right side: composition 
of the two selected quaternary systems; 
ternary systems quaternary systems 
PEG400 M250 M350 M500 DME250 DME500 M500 DME500 
+ CsA 
10 %     
+ Solutol 
5% 
8 %     20% 
6 %     (w/v) 
4 %     
+ CsA 
3 % 
2 % (w/v)    2 % 
1 %     1 % 
0.5 %     0.5 % 
0.25 %     0.1 % 
0.1 %     (w/v) 
+ stepwise 2 µl H2O; vortexing; turbidimetric measurement at λ = 550 nm 
calculation of the PoPs 
 
3.2.3. Tolerability towards HCEpiC cells in-vitro 
3.2.3.1. Cell culture 
Compatibility with HCEpiC cells in vitro was determined by observation of the cell 
volume. HCEpiC were cultured in the delivered corneal epithelial cell medium 
(CEpiCM) according to the supplier’s instructions. The cells were seeded on 13 mm 
glass slides and cultured until they showed confluence.  
3.2.3.2. Cell volume observation 
Due to the predominantly hyperosmotic conditions, the shift in cell volume was used 
as a significant parameter to investigate the compatibility of the solvents with the 
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HCEpiC. Therefore, the following samples were tested: an aqueous solution 
containing 10 % (w/v) Solutol, aqueous solutions containing 10 % (w/v) or 
20 % (w/v) M500 or DME500, respectively. A commercial 0.15 % sodium hyaluronate 
solution used as a lubricant for DED patients served as negative control. Volume 
detection was carried out using a superfusion system containing an Axiovert 40CFL 
microscope (Zeiss, Jena, Germany), a Coolsnap EZ camera (Fotometrix, Tucson, 
USA) and a perfusion chamber. The flow was set to 250 ml/h. The medium turnover 
took place within 30 s at a continuous flow. The period of observation was 25 min. It 
was split into 5 min flow of reference solution, a switch to sample solution for the next 
10 min and after this a switch back to the reference solution for 10 min. The pictures 
were taken over the whole period (1 frame = 3 s). The data was processed at the 
following time points: 0, 30, 150, 300, 330, 450, 600, 750, 930, 1200, 1350, 1500 s. 
The cell area served as a measure for the volume. The data were processed using 
the ImageJ software (National Institutes of Health, United States). 
The obtained data were statistically analyzed using a One Way RM ANOVA in 
combination with a Holm-Sidak method for pair wise multiple comparison at a 
significance level of p < 0.05 using SigmaPlot 11.0 (Systat Software Inc., San Jose, 
California, USA). 
3.2.4. Particle size measurements 
The particle size of the in-situ precipitate occurring upon contact with water was 
measured using dynamic light scattering (DLS). Samples were prepared in M500 and 
in DME500, respectively. The following combinations of drug and surfactant content 
were screened: 1 %, 5 %, 10 %, 15 % and 20 % (w/v) Solutol; 0 %, 0.1 %, 0.5 %, 
1.0 %, 2.0 % and 3.0 % (w/v) CsA. 30 µl of each sample dilution were filled in 1.5 ml 
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eppendorf cups (n = 3). These samples were precipitated with an excess of 770 µl 
H2O under gentle mixing. 400 µl of each sample were used to measure the particle 
size and the polydispersity index (PdI) with a Zetasizer Nano ZS (Malvern, 
Herrenberg, Germany). 
3.2.5. Scanning electron microscopy 
In order to visualize the resulting particles, a 3 % (w/v) solution of CsA in DME500 (A) 
without surfactant and a 3 % (w/v) solution of CsA in DME500 (B) stabilized with 
10 % Solutol (w/v) were precipitated as described in 3.2.4. The samples were 
prepared on a SpartanTM syringe filter membrane with a pore size of 0.2 µm by 
filtration of the dispersions, to exclude the solvents without any thermal impact on the 
system. The filter membranes were fixed on aluminum stubs using conductive carbon 
tape. Subsequently, micrographs were obtained by SEM using a Quanta 200 from 
FEI (Hillsboro, Oregon, USA). 
3.2.6. Solutions for in-vitro tissue uptake studies 
3.2.6.1. Preparation  
Tab. 3.2: INS solution design: INS solution at the PoP after instillation; compositions of the 4 INS 
solutions before application with varying amounts of water and DME500; 
 composition 
at the eye / 
PoP 
INS solutions 
 # 1 # 2 # 3 # 4 
CsA 1.00 % 1.30 % 1.30 % 1.30 % 1.30 % 
DME500 54.0 % 71.7 % 65.0 % 60.0 % 55.0 % 
Solutol 10.0 % 13.7 % 13.7 % 13.7 % 13.7 % 
Water 35.0 % 13.3 % 20.0 % 25.0 % 30.0 % 
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Four different solutions were prepared by dissolving 13 mg of CsA and 137 mg of 
Solutol in DME500 under gentle stirring. After a clear solution was obtained, the 
appropriate amount of water was added under constant stirring until the final 
formulation was transparent, colorless and visually free of air bubbles. The amounts 
of DME500 (A) and water (B) are shown in Tab. 3.2. The pH of the formulations was 
adjusted to 7.4 using 0.1 N HCl. 
3.2.6.2. Size and Charge 
The samples for the particle size measurement were prepared by precipitating 300 µl 
of each INS solution with 100 µl H2O and gentle mixing in a 1.5 ml eppendorf cup. 
Particle size and size distribution were measured by DLS. The samples for the zeta 
potential measurement were prepared by precipitating 750 µl of each sample with 
250 µl H2O and gentle mixing in a 1.5 ml eppendorf cup. The zeta potential was 
measured by laser doppler electrophoresis using a Zetasizer Nano ZS. 
3.2.6.3. Fluorescence microscopy 
In order to visualize the precipitated structures, the lipophilic dye Nile Red (NR) was 
added to the following samples: (A) H2O and (B) solution #1; Sample (C) was 
obtained by precipitation of 300 µl (B) with 100 µl H2O. From the precipitate of 
sample (C), sample (D) was kept after purification by centrifugation at 10.000 g over 
10 min and re-dispersion with 50 µl H2O. Microscopic pictures were taken with an 
Axiovert 200M inverse microscope equipped with a LSM510 laser scanning device, a 
Plan-Apochromat 63x (NA 1.4) objective and the AIM 4.2 software (Zeiss, Jena, 
Germany). An argon laser at a excitation wavelength of 488 nm was used. Emission 
was detected using a 580-615 nm band-pass filter.  
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3.2.7. In-vitro model for drug resorption 
Restasis® and a 2 % CsA olive oil solution served as reference solutions for the in-
vitro resorption studies. Solution # 1 (INS 1.0) and an INS containing 0.4 % CsA (INS 
0.4) were used as samples (Tab. 3.2). The INS 0.4 was prepared in analogy to the 
INS 1.0. The 2 % CsA olive oil solution was prepared by dissolution of CsA under 
gentle stirring for 2h at room temperature. The pH was adjusted to 7.4 with 0.1 N 
HCl.  
 
Fig. 3.1: Custom glass resorption chamber: the bottom glass is equipped with a little socket to place 
the eye; the top glass fixes and seals the eye; the cylindrical opening offers the option to instill 
preparations locally to the cornea; 
The enucleated pig eyes were supplied from a local abattoir and stored in isotonic, 
sterile sodium chloride solution until use. Custom made glass resorption chambers 
Chapter 3 
64 
 
(CRC) were manufactured by the University glassblower (Fig. 3.1). An eye was 
placed in the bottom well of the CRC and fixed with the top glass insert, so that the 
cornea was centered in the cylindrical opening (CO) of the upper part of the 
incubation chamber. The glass and the wet eye surface sealed the contact area so 
that no liquid from the CO was lost. 200 µl of the reference solutions were placed on 
the plane cornea. 150 µl of the INS solution were placed on the cornea together with 
50 µl of H2O to induce precipitation (the ratio 150 : 50 is equivalent to a 30 µl eye 
drop instilled into 10 µl of tear fluid at the anterior eye). The eyes were incubated with 
the solutions for 30 min at RT. Afterwards the top glass was removed and each eye 
was washed four times with 1 ml of a 5.2 % aqueous mannitol solution. The cornea 
was then excised with a surgical knife and homogenized by use of a tissue pulverizer 
(made by the university machine shop in analogy to the Bessman Tissue Pulverizer) 
and liquid nitrogen. The homogenized cornea were transferred into glass vials and 
weighed. To extract CsA, the tissue pieces were incubated under gentle stirring with 
1 ml MeOH, spiked with 100 ng/ml CsD as internal standard. After the extraction the 
suspension was centrifuged at 16.000 g for 15 min. 500 µl of the supernatant were 
filled in HPLC vials and stored at -80°C until further use. All samples were prepared 
and measured in triplicate. 
3.2.8. CsA analytics 
The UHPLC-MS analytics were performed in accordance to Rodriguez-Aller et al 
(2011) [38]. An Agilent Technologies UHPLC system equipped with a 6540 
quadrupole time of flight (Q-TOF) LC/MS system fitted with an Agilent jet stream 
electron spray ionization (AJS ESI) interface (Agilent Technologies Deutschland 
GmbH, Böblingen, Germany) was used. The chromatographic equipment consisted 
further of a high performance (HiP) autosampler G4226A with a sample volume of 
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2 µl and a storage temperature of 5 °C, a binary pump G4220A at a flow rate of 
0.6 ml/min and a column compartment G1316C with a column temperature of 70 °C. 
The AJS ESI was used in positive ion mode. Separation was performed on a Waters 
Aquity BEH c18, 1.7 u, 2.1 x 50 mm column (Waters Corporation, Milford, MA, USA). 
The mobile phase consisted of 40 % (A) H2O with 0,1 % formic acid (FA) and 60 % 
(B) methanol (MeOH) with 0.1 % FA. A gradient was applied for 3 min to 
concentrations of 0 % (A) and 100 % (B). Afterwards a re-equilibration was 
performed for 3 min. MassHunter Workstation software was used for data acquisition 
(Agilent Technologies Deutschland GmbH, Böblingen, Germany). Data handling and 
calculation were done using Microsoft Excel 2007 and Dintest 2004 software 
(ARVECON GmbH, Walldorf, Germany). 
The obtained data were analyzed using the t – test at a significance level of p < 0.05 
using SigmaPlot 11.0. 
3.3. Results and discussion 
3.3.1. CsA solubility in ternary systems (drug, solvent, water) 
First we investigated the solubility of the drug in ternary mixtures of CsA, PEG and 
water. Of special interest was the determination of the point of precipitation (PoP) i.e. 
the maximum water- content at which CsA would still be dissolved (Fig. 3.2).  
All solvents were able to solubilize at least 10 % (w/v) CsA, which is way far enough 
for an effective ocular dose which is discussed to be between 0.05 % (w/v) and 2.0 % 
(w/v) [14,19,39]. DME250 allowed for the highest water- content before a 
precipitation occurred. The lowest PoP was detected for PEG400. All other solvents 
ranged between these extremes. As expected, the critical water-content, on the one 
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hand increased with decreasing levels of CsA. On the other hand, it depended on the 
hydrophobicity and molar mass of the PEGs. The higher the degree of etherification 
and the lower the chain length, the more water was needed for a precipitation of CsA. 
In terms of tolerability, high levels of incorporated water are beneficial for a final 
formulation since this will lead to a lower osmotic pressure. Since tolerated osmotic 
pressure levels are limited (572mOsm [40] were reported) and lower for PEGs with 
higher molecular weight [41], we selected DME500 and M500 for all further studies. 
 
Fig. 3.2: Drug solubility: ternary systems of CsA, solvent and water at their PoP for different 
compositions; ( ) PEG400, ( ) M350, ( ) M250, (x) DME250, ( ) M500, ( ) DME500; 
3.3.2. CsA solubility in quaternary systems (drug, solvent, surfactant, water) 
To take advantage of the fact that a non-ionic surfactant may be beneficial for 
reducing the drug particle size after precipitation we investigated the solubility of CsA 
in quaternary systems of drug, solvent, surfactant (Solutol) and water (Fig. 3.3). 
Mixtures with M500 as solvent showed no difference in the critical water-content with 
or without the surfactant for CsA concentrations above 1 % (w/v) (Fig. 3.3 A).  
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Fig. 3.3: Drug solubility: quaternary systems, consisting of drug, surfactant, solvent and water; [A] 
system with M500 as solvent; [B] system with DME500 as solvent; Solutol as a surfactant was used in 
concentrations of 0 % ( ), 5 % ( ) and 20 % ( ); 
At lower concentrations, the critical water-content could even be increased up to 
80 % (w/v). The maximum water-content was also independent of the surfactant 
concentration in a range between 5 % (w/v) and 20 % (w/v) Solutol. Mixtures with 
DME500 as solvent, in contrast, showed a slightly different behavior (Fig. 3.3 B). 
Below CsA concentrations of 2 % (w/v) the surfactant increased the critical water-
content continuously compared to the ternary system. The highest levels were again 
about 80 % (w/w) water. The PoP was again independent of the surfactant 
concentration in a range between 5 % (w/v) and 20 % (w/v) Solutol. 
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3.3.3. Compatibility towards HCEpiC cells in-vitro 
The cells showed a decrease in cell area upon exposition to any solution even 
classical Ringer’s solution (data not shown). Only the cell culture medium delivered 
with the cells was accepted without any loss in cell area. Fig. 3.4 A shows the 
decrease in the cell area of a commercially available 0.15 % sodium hyaluronate 
solution (SHS) and an aqueous solution of 10 % (w/v) Solutol. For both solutions 
after 1500 seconds a shrinking down to 76.1 ± 2.1 % and 71.6 ± 3.8 %, respectively, 
of the initial cell area could be detected. In a next step aqueous mixtures of Solutol 
and solvent were compared with SHS. Fig. 3.4 B shows the change of cell area with 
time upon exposition to the four different solutions. The first differences to SHS were 
observed with the medium change to the sample solution at 330 s, what seemed to 
be due to their hypertonicity. This also explained the more abrupt decrease with [b] 
and [d] containing 20 % (w/v) of solvent [42]. [b] showed here the most significant 
decrease. Until 930 s, the cell area declined continuously, but much less with [c] 
(75.9 ± 3.2 %) and [d] (78.1 ± 1.9 %) compared to [a] (69.6 ± 2.9 %) and [b] 
(69.2 ± 4.4 %). After medium change back the cell area stayed constant. At 1500 s, 
the endpoint of observation, sample [d] showed the significantly highest levels (Tab. 
3.3). An initial loss of water and the corresponding decrease in cell area within the 
first few seconds is typical for hypertonic stress on cells [43]. After this response to 
the “osmotic stress”, the cell area decrease equilibrated as described by Zhou et al 
[42]. 
Due to less shrinking upon contact with the solutions containing DME500, it seemed 
to be the most promising solvent in terms of a later application at the anterior eye. 
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Fig. 3.4: Tolerability: [A] effect on the cell volume caused by the exposure with the aqueous mixtures 
of 10 % Solutol ( ) compared to a aqueous 0.15 % sodium hyaluronate solution ( ); [B] comparison 
of the change of cell volume caused by the exposure with aqueous mixtures of M500 and Solutol, 
and DME500 and Solutol with the aqueous 0.15 % sodium hyaluronate solution: [a] 10 % (w/v) Solutol 
/ 10 % (w/v) M500 ( ); [b] 10 % (w/v) Solutol / 20 % (w/v) M500 ( ); [c] 10 % (w/v) Solutol / 
10 % (w/v) DME500 ( ); [d] 10 % (w/v) Solutol / 20 % (w/v) DME500 ( );  
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Tab. 3.3: Tolerability: significant differences determined by one way RM ANOVA at the medium switch 
(300s), after the medium switch (330s), at the medium switch back (930s) and at the end of 
observation (1500s) for [A] 10% M500 / 10% Solutol [B] 20% M500 / 10% Solutol, [C] 
10% DME500 / 10% Solutol, [D] 20% DME500 / 10% Solutol and [R] the reference eye drop solution 
BLUyal®; *** = p < 0,05 (One Way RM ANOVA); 
time / 
sec 
[A]  
vs.  
[R] 
[A]  
vs.  
[B] 
[A]  
vs. 
[C] 
[A]  
vs.  
[D] 
[B]  
vs.  
[R] 
[B]  
vs.  
[C] 
[B]  
vs.  
[D] 
[C]  
vs.  
[R] 
[C]  
vs.  
[D] 
[D]  
vs.  
[R] 
300           
330  ***   *** ***     
930       ***    
1500    ***   ***  *** *** 
           
3.3.4. Particle size screening 
In order to prove the concept of the INS we investigated the particle size of CsA 
crystals upon precipitation. The CsA concentration ranged from 0 %, to detect the 
micelle size in the drug- free system, to 3.0 % (w/v). The Solutol concentrations 
ranged between 1 % and 20 % (w/v). M500 and DME500 were used as solvents. A 
high excess of water was added to guarantee a complete precipitation. With few 
exceptions all samples showed average particles with sizes below 250 nm (Fig. 3.5 
A, B). In general it could be shown, that increasing concentrations of drug led to 
increasing particle sizes. The most consistent results for both solvents in this setup 
were achieved using a surfactant concentration of 5 % Solutol. With M500 as solvent 
(Fig. 3.5 A, C) the particle size distributions as reflected by the PdI were broader. The 
samples made with DME500 (Fig. 3.5 B, D) showed similar particle sizes but 
substantially narrower particle size distributions with mean PdIs below 0.3. At 0.1 % 
(w/v) CsA the particles showed nearly the same size as the plain micelles. In the 
presence of 20 % (w/v) Solutol even the 0.5 % (w/v) CsA sample only showed this 
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size. Due to the inhomogeneous PdIs (Fig. 3.5 A, C), this clear separation between 
precipitation and micellar structures could not be shown with M500. Instead, 
tremendous differences in terms of a reproducible, homogeneous precipitation were 
observed for the two solvents. The variation of the surfactant concentration showed 
no significant impact on the particle size [44]. As shown for the solubility in 
quaternary systems, it was more the presence than the concentration of surfactant 
that had a remarkable effect on the wetting of the precipitate.  
 
Fig. 3.5: Particle size screening: particle size (upper row) and corresponding polydispersity indices 
(lower row) of the precipitated structures as a function of drug- and surfactant concentration; left panel: 
formulations with M500 as a solvent; right panel: formulations with DME500 as a solvent;  
( ) 0 % CsA, ( ) 0.1 % CsA, ( ) 0.5 % CsA, ( ) 1.0 % CsA, ( ) 2.0 % CsA, ( ) 3.0 % CsA; 
Only at the lowest (1 %) or highest concentration (20 %) differences were visible, but 
not necessarily significant. The most deciding factor with impact on the particle size 
was the concentration of CsA. In general, as known from literature, with higher 
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amounts of CsA, larger particles occurred [44]. With M500 as solvent (Fig. 3.5 A, C) 
the particle size distributions as reflected by the PdI were broader. The samples 
made with DME500 (Fig. 3.5 B, D) showed similar particle sizes but substantially 
narrower particle size distributions with mean PdIs below 0.3. At 0.1 % (w/v) CsA the 
particles showed nearly the same size as the plain micelles. In the presence of 20 % 
(w/v) Solutol even the 0.5 % (w/v) CsA sample only showed this size. Due to the 
inhomogeneous PdIs (Fig. 3.5 A, C), this clear separation between precipitation and 
micellar structures could not be shown with M500. Instead, tremendous differences in 
terms of a reproducible, homogeneous precipitation were observed for the two 
solvents. The variation of the surfactant concentration showed no significant impact 
on the particle size [44]. As shown for the solubility in quaternary systems, it was 
more the presence than the concentration of surfactant that had a remarkable effect 
on the wetting of the precipitate. Only at the lowest (1 %) or highest concentration 
(20 %) differences were visible, but not necessarily significant. The most deciding 
factor with impact on the particle size was the concentration of CsA. In general, as 
known from literature, with higher amounts of CsA, larger particles occurred [44]. 
The effect of the surfactant Solutol was proven, using environmental scanning 
electron microscopy (eSEM). Fig. 3.6 illustrates a non stabilized sample (A) and 
sample (B) stabilized with 10% Solutol. Precipitate (A) showed a compact layer of 
precipitate. The filter membrane was not visible. No single, defined structures were 
detected. Precipitate (B) visualized aggregates of single spherical particles with a 
size above 200 nm (Fig. 3.6, white circles). The aggregates seemed to be due to the 
filtration pressure during the preparation. Because of the fact, that the bulk of the 
precipitate could be filtrated and thus, was not visible on the membrane, the single 
particles were presumably sized below 200 nm. 
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Fig. 3.6: Particle size screening: eSEM pictures of the precipitate of (A) 3% CsA/DME500 without a 
stabilizing surfactant and (B) 3% CsA/DME500 with 10% Solutol as stabilizing surfactant on a 0.2 µm 
filter membrane; the white spots mark some single particles and agglomerates exemplarily; 
This fitted the results of the PCS with a size of 194.97 ± 3.27 nm (Fig. 3.5). The 
presence of surfactant had a tremendous impact on the precipitation. With Solutol 
homogeneous dispersed systems, without, non defined, agglomerated cloudy 
structures occurred. Due to a re-dissolving of the particles while the sample 
preparation after the evaporation of the aqueous phase and thus an excess of 
solvent, the observation using a non environmental SEM was not possible. 
3.3.5. Development and characterization of INS solutions for in-vitro 
resorption studies 
In order to obtain a promising composition for subsequent in-vitro investigations in a 
porcine model, four INS solutions were designed and characterized with respect to 
their particle size, size distribution and zeta- potential. 
3.3.5.1. Development of the INS solutions 
The design of the solutions was based on the solubility studies in quaternary systems 
using DME500 as solvent. Due to the missing knowledge on precipitation and 
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resorption in-vivo, a PoP concentration of 1 % (m/m) CsA was chosen for the 
development. Its composition at the eye / PoP is shown in Tab. 3.2. Upon this 
composition, the four different solutions were calculated by lowering the water- 
content to reach a varying water excess at the PoP. The calculation is based on the 
hypothesis that a tear volume of about 10 µl is present at the ocular surface and a 
droplet of 30 µl is instilled [45,46]. Sample #1 was configured by subtraction of this 
amount of tear volume from the aqueous fraction at the PoP. The samples #2, #3 
and #4 were configured by lowering the content of DME500 and an increase of the 
amount of water. 
3.3.5.2. Characterization of the INS solutions 
The four different solutions were characterized in terms of particle size, size 
distribution and zeta potential using dynamic light scattering and laser doppler 
electrophoresis, respectively. The results are shown in Tab. 3.4. 
Tab. 3.4: Solution characterization: particle size, size distribution and zeta potential of the four 
solutions with varying amounts of DME500 and  H2O upon precipitation; 
INS solution ZAV / nm PdI η-potential / mV 
# 1 697 ± 19 0.110 ± 0.051 -0.01 ± 0.11 
# 2 885 ± 15 0.111 ± 0.048 -0.115 ± 0.1 
# 3 505 ± 5 0.230 ± 0.029 -0.07 ± 0.05 
# 4 487 ± 7 0.440 ± 0.075 -0.05 ± 0.13 
 
All precipitated samples showed particle sizes below 900 nm. The initial water- 
content of the solutions had a huge impact on the particle size. With a higher excess 
of water at the PoP, smaller particles were detected. Solutions #1 and #2 with 13 % 
and 20 % H2O, respectively, showed particles with a size of 697 ± 19 nm and 885 ± 
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15 nm. However, the solutions #3 and #4 with higher amounts of water obviously led 
to smaller particles of 505 ± 5 nm and 487 ± 7 nm, respectively. Due to their 
submicron size, as previously reported these particles might be suitable for 
endocytotic uptake into cornea cells [47]. They could then act like a reservoir, and 
release the drug to the surrounding tissues [17]. In contrast to the size, the PdI 
increased with higher water- content, similarly as reported by Ford et al. (1999) for 
CsA nanoparticles out of an acetonic solution [44]. Hence, solution #4 with the 
smallest ZAV showed the highest PdI. Solution #1 (PdI = 0.110 ± 0.051) and #2 
(PdI = 0.111 ± 0.048) had a nearly monomodal size distribution. In general, solution 
#3 showed the best performance with a size of 505 ± 5 nm and a PdI of 0.230 ± 
0.029. As expected and due to the missing charges in the molecules, a nearly neutral 
zeta potential was determined for all solutions. 
 
Fig. 3.7: Solution characterization: fluorescence microscopic pictures of Nile Red (NR) stained 
samples; (A) H2O + 0.01% NR; (B) INS #1 + 0.01 % NR before precipitation; (C) INS #1 + 0.01 % NR 
after precipitation; (D) sample (C) after centrifugation and re-dispersion in H2O; 
In order to visualize the precipitate as well as the homogeneity of the unprecipitated 
solution, fluorescence microscopic pictures were taken (Fig. 3.7). Nile Red, which 
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shows fluorescence only in lipophilic environment, was used as dye, as similarly 
done previously as hydrophobic model drug for micellar systems [26]. Due to the 
missing hydrophobic environment in water, the blank (A) showed neither 
fluorescence, nor structures in the transmitted light channel. Solution #1 (B) showed 
a homogeneous fluorescence all over the sample. This was belike to the micelle 
formation of Solutol. Solutol micelles were typically around 13 nm (data not shown) 
as also reported in literature [48]. After (B) was precipitated, besides homogeneous 
background fluorescence, red dots ranging from some nanometers to aggregates of 
a few micrometers were observed (C). It could be possible, that NR precipitated on 
its own and was stabilized by Solutol. However, because of the very low amounts of 
NR used, it might be more suitable, that it was attached to the lipophilic CsA-
precipitate. The aggregates may be due to the mechanical influence while the 
preparation on the glass slides. (C) was centrifuged and the precipitate was re-
dispersed in water (D). Due to the centrifugation, some agglomerates in a range of 
about 10 µm were observed. Besides these, no further background fluorescence was 
disturbing. In contrast to (C) with many aggregates of a few micrometers, less of 
those but much more single particles in the upper nanometer scale appeared. As 
expected, the transmitted light channel just showed the big fuzzy agglomerates. With 
respect to the mechanical influence while sample preparation for microscopy, in 
comparison to the sample preparation for DLS, where nearly no mechanical influence 
occurred, the results from (D) and the PCS of solution #1 (ZAV = 697 ± 19 nm) fit and 
support each other. 
3.3.5.3. Drug resorption using a porcine in vitro model 
To prove the suitability of the INS as a therapeutic application system for the anterior 
eye, solution #1 was investigated in terms of corneal CsA uptake in-vitro using a 
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enucleated porcine eye model. To gather further information on the concentration 
dependent uptake and to see if a further dose reduction would be feasible, an INS 
containing only 0.4 % CsA was additionally investigated. 
 
Fig. 3.8: In-vitro resorption: amount of CsA taken up by porcine-cornea from 200µl sample solution 
over a period of 30 min; samples: INS 1.0 (1 % CsA), INS 0.4 (0.4 % CsA) Restasis® (0.05 % CsA 
microemulsion), Oil (2 % CsA olive oil solution); ** = P < 0.01(t-test); screening was performed in 
triplicate; 
The INS solutions were compared to Restasis® and a 2 % CsA olive oil solution (Fig. 
3.8). The final sample volume was 200 µl to get a complete wetting of the cornea. 
After 30 min, a typical half life time after single instillation [35], the mean corneal drug 
concentrations were 3165 ± 597 ngCsA/gcornea and 3345 ± 744 ngCsA/gcornea for the 1 % 
INS and the 0.4 % INS, respectively. Both were significantly above the amounts 
detected for Restasis® (545 ± 138 ngCsA/gcornea) and the oily solution 
(452 ± 143 ngCsA/gcornea). Despite its very high CsA concentration, which is a fifth of 
the 0.4 % INS content and 40 fold of Restasis®, the oily solution did not show 
significantly different tissue levels compared to Restasis®. The 0.4 % INS already 
seemed to reach maximum possible cornea levels, which did not significantly differ 
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from those reached by the 1 % INS. This may be due to the smaller size of the 
nanoparticles resulting from lower CsA concentrations of the INS (compare results of 
the particle size screening, 3.3.4) 
Compared to in-vivo studies with rats, where Restasis® did not show quantifiable 
CsA levels in corneal tissue after twice a day administration over 5 days, [35], we 
could detect CsA after administration of Restasis®, but far below the levels after an 
administration of the INS solutions. Daull et al detected 20 min after an instillation of 
50 µl in-vivo only slightly higher levels for Restasis® (748 ± 129 ngCsA/gcornea) then 
our group. Further, after one week with instillations of 50 µl Restasis® twice a day, 
the tissue levels reached not more than 1072 ± 369 ngCsA/gcornea [49]. Therefore, we 
assume for our INS solutions after instillation of a typical droplet (25 µl) in vivo 
corneal levels significantly above those of Restasis® and the therapeutic tissue 
levels for CsA (50 – 300 ngCsA/gcornea) as reported by Kaswan et al [50]. It seems, 
Restasis® and the oily solution, suffered from the higher affinity of CsA to the 
lipophilic vehicle compared to the hydrophilic milieu of the cornea [9]. Even thus the 
instilled volume (200 µl) of our in-vitro investigations had to be higher than a usual 
eye drop to guarantee a complete wetting of the corneal surface, the similar tissue 
levels of Restasis® detected by our group and Daull et al proved the comparability of 
our in-vitro system. Hence, our INS is a promising approach to increase the 
bioavailability of CsA and eventually lower the number of instillations per day 
significantly. This may help to increase the patients’ compliance [34,35,51]. 
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3.4. Conclusion 
In the present work we developed an “in-situ nanosuspension” to overcome the 
problems associated with the administration of poorly soluble drugs, such as CsA, at 
the anterior eye. The INS is a clear, transparent preparation, without a cumbersome 
production and a simple application regimen. It is able to solubilize high amounts of 
CsA and precipitates CsA into nanosized, stabilized particles upon contact with 
aqueous fluids. The compatibility with a corneal cell line was observed as good as 
ophthalmic solutions like a commercial aqueous 0.1 % sodium hyaluronate solution. 
After single instillation of the INS in a porcine cornea model in-vitro promisingly high 
CsA levels were obtained in the tissue. 
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Abstract 
The efficient treatment of diseases at the anterior segment of the eye with potent, but 
poorly soluble drug is a major issue in research. In this study we developed a self- 
assembling micellar system for budesonide and cyclosporin A (CsA), which was 
investigated in terms of its solubilizing qualities, particle size and morphology, 
compatibility and drug resorption into porcine cornea in-vitro. The clear and colorless 
solutions dissolved both drugs in a concentration dependent manner just by use of 
gentle stirring and without further organic solvent or mechanical influences in 
significant higher concentrations compared to their solubility in water. The 
poly(ethylene glycol) fatty alcohol ethers Sympatens AS and Sympatens ACS 
showed the best performance. The micelles had a size from 9.4 ± 0.03 nm to 12.7 ± 
0.04 nm, in which Solutol led to the biggest micelles and the CsA loaded ones, no 
matter which surfactant was used, were slightly smaller, than the budesonide loaded 
and drug- free micelles. The size and spherical shape was proven by transmission 
electron microscopy. The solutions were tolerated by primary human epithelial 
cornea cells in-vitro as well as the control. Finally, in an in-vitro porcine cornea 
model, the 0.05 % CsA micellar solution showed with 1557 ± 407 ngCsA/gcornea 
significantly higher tissue levels then Restasis® (545 ± 137 ngCsA/gcornea) and a 
typically used 2 % CsA oily solution (452 ± 142 ngCsA/gcornea). In conclusion, the data 
demonstrate a promising and powerful approach for the application of poorly soluble 
drugs towards the treatment of diseases like for example dry eye disease or age-
related macular degeneration (ArMD). 
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4.1. Introduction 
Local therapy at the anterior eye for the treatment of inflammatory diseases, such as 
dry eye disease (DED), is still a highly unmet need. Contemporary research focuses 
on increasing the bioavailability and the therapeutic efficiency of drugs and on 
avoiding their systemic side effects [1–4]. Two examples for highly potent anti-
inflammatory drugs are budesonide and cyclosporin A (CsA). Due to its potential to 
inhibit the expression of vascular endothelial growth factor (VEGF), budesonide, with 
a 200 fold higher affinity for the corticoid receptor than dexamethasone [5], might be 
an option in the local therapy of age related macular degeneration (ARMD) [6]. CsA 
on the other hand, is successfully used in the treatment of uveitis [7], necrotizing 
scleritis [8] or thyroid ophthalmopathy [9] and is one of the most promising 
substances for the treatment of dry eye disease [10]. Unfortunately, both potent 
drugs suffer from their insufficient solubility in aqueous media (budesonide, 14 µg/ml 
in water [11]; CsA, 6.6 µg/ml in water [12]) and their high octanol-water-coefficient of 
logP = 3.2 [6] and logP = 3 [13] for budesonide and CsA, respectively. Therefore, 
there have been numerous formulation efforts to administer these drugs for a number 
of treatments. Budesonide, which is typically used in treatment of pulmonary 
diseases is usually administered via a dry powder inhaler (Pulmicort® Turbohaler®) 
or a suspension (Pulmicort® Suspension; Pulmicort® Topinasal®). Sahib. et al 
developed a sterically stabilized micellar system, which is able to dissolve 
approximately 600 µg/ml budesonide, but suffers from a cumbersome way of 
production [14]. Many different options, with a main focus on colloidal systems like 
micelles [15,16], liposomes [17] or various nanoparticular formulations [18–20] were 
investigated to solubilize CsA. A cationic nanoemulsion is currently in clinical trial 
phase III and Restasis® (Allergan) a 0.05 % CsA microemulsion is the only approved 
Chapter 4 
88 
 
product, however, on the US market only [21]. Hence, dry eye syndrome is typically 
treated with 2 % CsA oily eye drops, using vegetable oils as solvent [22,23]. But, all 
systems containing an oily phase usually come with side effects like burning, stinging 
sensation and blurry vision. Due to this fact, the patient compliance is very low [24]. 
Even though there was a lot of research done in the past, there is still a tremendous 
need for a simple, but yet efficient aqueous colloidal system, which does not need 
any oil phase. Made of inexpensive surfactants it should self assemble in the 
presence of water and drug of which it should solubilize large amounts. Such a 
formulation would come with a tremendous increase of the patient compliance and 
would be a major option in the causal treatment of various diseases at the anterior 
segment of the eye. 
The aim of our study was to develop such a self-assembling micellar system. Of high 
interest was, thereby, its in-vitro tolerability and drug resorption in a porcine in-vitro 
model.
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4.2. Materials and methods 
4.2.1. Materials 
Cyclosporin A (CsA), budesonide and BLUyal® UD a 0,15 % aqueous sodium 
hyaluronate solution were supplied by the Pharma Stulln GmbH (Stulln, Germany). 
Cyclosporin D (CsD) was a kind gift of Prof. Dr. F. Kees (University of Regensburg, 
Regensburg). Solutol® HS 15 was a kind gift from the BASF (Ludwigshafen, 
Germany). Sympatens AS/200G (AS) and Sympatens ACS/200G (ACS) were 
provided by KOLB (Hedingen, Switzerland). Nile Red (NR) and pyrene were 
purchased from Sigma-Aldrich Chemie GmbH (Taufkirchen, Germany). Mannitol was 
purchased from Caesar & Loretz GmbH (Hilden, Germany). Deionized water was 
obtained from a Milli-Q	   water purification system from Millipore (Schwalbach, 
Germany). Primary human cornea epithelial cells (HCEpiC) and corneal epithelial cell 
medium (CEpiCM) were purchased from Sciencell Research Laboratories (Carlsbad, 
USA). Methanol (MeOH), acetonitrile (MeCN), isopropanol (all HPLC grade) and 
chloroform p.a. were purchased from Merck (Darmstadt, Germany). 0.1 N 
hydrochloric acid  and 0.1 N sodium hydroxide solution were obtained from Carl Roth 
(Karlsruhe, Germany). 
4.2.2. Determination of the critical micelle concentration (CMC) 
The critical micelle concentration of the three surfactants was determined using a 
fluorescence spectroscopy method [25,26]. To determine the critical micelle 
concentration pyrene aliquots of 1 mg per vial were prepared. Hence, 120 mg of 
pyrene were dissolved in 3000 µl of chloroform. 120 glass vials (2 ml Screw top vial; 
BGB Analytik AG, Rheinfelden, Germany) were filled with 25 µl of this solution using 
a positive displacement pipette (Multipette® plus; Eppendorf AG, Hamburg, 
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Germany) and the solvent was evaporated using a stream of nitrogen gas. The vials 
were caped and stored under exclusion of light at room temperature until further use. 
Aqueous stock solutions (1 ml) of the three surfactants with concentrations of 
0.1 % (w/v) for Solutol and 1.0 % (w/v) for AS and ACS were prepared. They were 
diluted with water to 6 different concentrations: 0.1, 0.05, 0.01, 0.005, 0.001, 0.0001, 
0 % (w/v) for Solutol; 1.0, 0.1, 0.01, 0.001, 0.0001, 0.00001 % (w/v) for AS and ACS.  
200 µl of each dilution was filled in a vial containing a pyrene aliquot (n=3). The vials 
were incubated under shaking for 24 h at room temperature. Afterwards, 150 µl of 
each vial were transferred to eppendorf cups and centrifuged at 12.000 g for 10 min 
with a Centrifuge 5415 R (Eppendorf AG, Hamburg, Germany). 100 µl of the 
supernatant were transferred in a 96 multiwell plate. Pyrene was exited at a 
wavelength of 339 nm and its emission was recorded at 390 nm using a PerkinElmer 
LS55 Fluorescence Spectrometer (PerkinElmer LAS GmbH, Rodgau-Jügesheim, 
Germany). The mean fluorescence intensity was plotted against the log of the 
surfactant concentration of AS, ACS and Solutol. 
4.2.3. Solubility enhancement 
Aqueous stock solutions of the surfactants were prepared at concentrations of 5, 10 
and 20 % (w/v) under gentle stirring. 30 mg of CsA and 5 mg budesonide, 
respectively, were added to 1 ml of the surfactant solutions (n=3) and stirred for 24 h 
at room temperature in glass vials. Afterwards, the dispersions were transferred into 
Eppendorf cups and centrifuged at 16.000 g for 10 min. 100 ml of the supernatant 
were diluted with 900 µl of MeOH in HPLC vials (2 ml Screw top vial; BGB Analytik 
AG, Rheinfelden, Germany) and stored at -80 °C (HERAfreeze; Thermo Fischer 
Scientific GmbH, Ulm, Germany) until further use. 
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As an external standard, concentrations of CsA in MeOH of 10 %, 7.5 %, 2.5 %, 
1.0 %, 0.75 %, 0.5 %, 0.25 % and 0.1 % (w/v) were used. The external standard 
concentrations of budesonide were 1 %, 0.75 %, 0.25 %, 0.10 %, 0.075 %, 0.05 %, 
0.025 % and 0.01 % (w/v). The quantitative analysis of the residual drug content was 
carried out using high pressure liquid chromatography (HPLC).  
For the cyclosporin A analytics, a Shimadzu chromatographic setup consisting of a 
SCL-10AVP controller, a LC-10ATVP pump at a flow rate of 1 ml/min, a SIL-10ADVP 
autoinjector with a sample volume of 15 µl, a CTO-10ASVP oven with a temperature 
of 75°C and a SPD-10AVP UV detector at a wavelength of 210 nm were used (all from 
Shimadzu Deutschland GmbH, Duisburg, Germany). A reversed octadecyl column 
Luna 3µ C18(2) 100A with 100 x 4.6 mm served as solid phase (Phenomenex, 
Aschaffenburg, Germany). The mobile phase consisted of 75 % MeCN and 25 % 
H2O and was linearly decreasing to 90 % MeCN and 10 % H2O over 5 min. These 
concentrations were kept until 12.5 min and afterwards the column was re-
equilibrated to the initial conditions until the end of the run at 15 min. 
The chromatographic conditions for the budesonide analytics were in general as 
described for CsA with slightly different parameters. The injection volume of the 
autoinjector was set to 10 ml, the oven temperature was set to 22 °C and UV 
detection was carried out at 244 nm. An isocratic elution was carried out with a 
methanol – water mixture (80:20, v/v) over 5 min. 
4.2.4. Drug- loaded micelle preparation 
100 ml of a isotonic 5.2 % (w/v) mannitol aqueous solution (MAS) were prepared by 
gentle stirring. 30 ml of surfactant stock solutions (SSS) with concentrations of 5 % 
(w/v) AS, 5 % (w/v) ACS and 10 % (w/v) Solutol, respectively, were prepared by 
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dissolving the surfactants in MAS under gentle stirring. 100 mg CsA and 10 mg 
budesonide, respectively, were dissolved in 10 ml of each SSS by gentle stirring. The 
pH was adjusted to 7.4 and the SSS were stored at 4 °C until use. 
4.2.5. Micelle size and zeta- potential measurements 
The particle size and the polydispersity index, as a measure of size distribution of the 
micelles was measured by dynamic light scattering (DLS) using a Zetasizer Nano ZS 
(Malvern, Herrenberg, Germany). The sample volume in the poly styrene semi-micro 
cuvettes was 400 µl. The zeta potential was measured in folded capillary cells 
(Malvern, Herrenberg, Germany) with a sample volume of about 1 ml by laser 
doppler electrophoresis using a Zetasizer Nano ZS.  
The obtained data were analyzed using a One Way RM ANOVA in combination with 
a Holm-Sidak method for pair wise multiple comparison at a significance level of 
p < 0.05 using SigmaPlot 11.0 (Systat Software Inc., San Jose, California, USA). 
4.2.6. Micelle characterization by transmission electron microscopy 
Micelle size and shape of a drug- free of 5 % ACS aqueous solutions was visualized 
by transmission electron microscopy (TEM) using a negative staining technique. 
Therefore, 2 µl of the sample solution were dried on the surface of carbon coated 
copper grids (400 mesh; Plano GmbH, Wetzlar, Germany). The sample was stained 
using a 2 % (w/v) uranylacetate aqueous solution. Images were recorded using a 
Philips CM12 transmission electron microscope (FEI Electron Optics, Eindhoven, 
Netherlands) equipped with a slow scan CCD camera TEM1000 (TVIPS, Tietz 
GmbH, Gauting, Germany). Particle size was determined by measuring 100 micelles 
using the ImageJ software (National Institutes of Health, United States). 
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4.2.7. Entrapment efficiency 
Four different surfactant concentrations were prepared to determine their entrapment 
efficiency of 0.1 % drug. To solubilize CsA aqueous solutions of 1 %, 0.7 %, 0.3 % 
and 0.1 % (w/v) AS and ACS, respectively, for budesonide concentrations of 3 %, 
2 %, 1 % and 0.7 % (w/v) of the surfactants were prepared by gentle stirring.  
1 ml of each concentration was spiked with 1 mg of CsA and budesonide, 
respectively, and stirred for 24 h at room temperature (n=3). The dispersions were 
centrifuged at 16.000 g for 10 min using eppendorf cups. 100 µl of the supernatant 
were diluted with 900 µl MeOH in HPLC vials (2 ml Screw top vial; BGB Analytik AG, 
Rheinfelden, Germany). The samples were stored at -80 °C (HERAfreeze; Thermo 
Fischer Scientific GmbH, Ulm, Germany) until further analysis. 
The CsA and budesonide concentrations were determined by HPLC measurements 
as described under 4.2.3.  
The entrapment efficiency E was calculated as 
𝐸 % =    𝑐!!𝑐!! + 𝑐!!𝑐!! + 𝑐!!𝑐!!3    ∙ 100 
were cn was the determined concentration in the sample, which was divided through co, the initial concentration of 0.1 % drug for each of the three measurements. The 
average was calculated by division through n = 3 and finally, the relative entrapment 
efficacy E was held by multiplication with 100. 
4.2.8. Compatibility of micelles with cornea cells 
Compatibility with HCEpiC cells, a primary human cornea epithelial cell line, was 
determined in vitro by observation of the volume control of the cells. HCEpiC were 
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cultured in the delivered corneal epithelial cell medium (CEpiCM) according to the 
supplier’s instructions. The cells were seeded on 13 mm glass slides and cultured 
until they showed confluence.  
An aqueous solution containing 10 % (w/v) Solutol, an aqueous solution of 5 % (w/v) 
AS and an aqueous solution of 5 % (w/v) ACS were investigated as colloidal 
vehicles. BLUyal®, a 0.15 % sodium hyaluronate solution was used as negative (i.e. 
biocompatible) control. Volume detection was carried out using a superfusion system 
containing an Axiovert 40CFL microscope (Zeiss, Jena, Germany) equipped with a 
Coolsnap EZ camera (Fotometrix, Tucson, USA) and a perfusion chamber. The flow 
rate was set to 250 ml/h. The medium turnover took place within 30 s at a continuous 
flow. The period of observation was 25 min. It was split into 5 min flow of reference 
solution, a switch to sample solution for the next 10 min and after this a switch back 
to the reference solution for 10 min. The pictures were taken over the whole period (1 
frame = 3 s). The cell area served as a measure for the volume. The data were 
processed using the ImageJ software. 
The obtained data were analyzed using a One Way RM ANOVA in combination with 
a Holm-Sidak method for pair wise multiple comparison at a significance level of 
p < 0.05 using SigmaPlot 11.0. 
4.2.9. In-vitro model for drug resorption 
The experiments were conducted as described by Luschmann et al 2013 [27]. In 
brief: Enucleated pig eyes were supplied from a local abattoir and stored in isotonic, 
sterile sodium chloride solution until use. An eye was placed in the CRC and fixed. 
200 µl of the solutions were placed on the plane cornea. The eyes were incubated for 
30 min at room temperature. Each eye was washed four times with 1 ml of aqueous 
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5.2 % (w/v) mannitol solution. The cornea were excised with a surgical knife and 
homogenized by use of a tissue pulverizer (made by the university machine shop in 
analogy to the Bessman Tissue Pulverizer) and liquid nitrogen. To extract CsA, the 
tissue pieces were incubated for 2 hours under gentle stirring with 1 ml MeOH, and 
spiked with 100 ng/ml CsD as internal standard. After the extraction the suspension 
was centrifuged at 16.000 g for 15 min. 500 µl of the supernatant were filled in HPLC 
vials and stored at -80°C until further use. All samples were prepared and measured 
in triplicate. 
4.2.10. Chromatographic method and equipment 
The UHPLC-MS analyses were performed as described by Luschmann et al 
2013[27]. In brief: An Agilent Technologies UHPLC system equipped with a 6540 
quadrupole time of flight (Q-TOF) LC/MS system (Agilent Technologies Deutschland 
GmbH, Böblingen, Germany) was used. Separation was performed on a Waters 
Aquity BEH c18, 1.7 u, 2.1 x 50 mm column. The mobile phase consisted of 40 % (A) 
H2O with 0.1 % formic acid (FA) and 60 % (B) methanol (MeOH) with 0.1 % FA. A 
gradient was applied for 3 min to concentrations of 0 % (A) and 100 % (B). 
Afterwards a column re-equilibration was performed for 3 min. 
The obtained data were analyzed using the t – test at a significance level of p < 0.05 
using SigmaPlot 11.0. 
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4.3. Results and discussion 
4.3.1. Manufacture of drug- loaded micelles 
 
Fig. 4.1: Micelle characterization; determination of the CMC of [A] Sympatens AS and [B] Sympatens 
ACS and [C] Solutol by use of a pyrene fluorescence assay; 
First of all we determined the surfactant concentration that was to be exceeded to 
obtain micelles. The observed CMCs were 0.0054 %, 0.0038 % and 0.0109 % (w/v) 
for AS, ACS and Solutol, respectively (Fig. 4.1).This is for Solutol in accordance with 
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the literature values [28], but for AS and ACS about 10 times higher than reported by 
the manufacturer. 
 
  
Fig. 4.2: Solubility: maximum solubility of [A] budesonide and [B] cyclosporin A by use of different 
concentrations of the non-ionic surfactants Sympatens AS ( ), Sympatens ACS ( ) and Solutol ( ); 
Depending on the formulation, CsA and budesonide are typically applied in 
concentrations of 0.05 – 2,0 % (w/v) [29–31] and 0.025 – 0.05 % (w/v) [32], 
respectively. Since the solubility of both drugs in water is considerably lower, we 
explored the potential of the surfactants to increase drug solubility in water.  
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In general, all surfactants solubilized CsA and budesonide in a concentration 
dependent manner (Fig. 4.2). The highest levels for budesonide of 0.132 % (w/v), 
which are far above the typical therapeutic dosing, were reached with a surfactant 
concentration of 20 % Solutol, however, this was already possible with 5 % (w/v) of 
AS and ACS, respectively. At these surfactant concentrations approximately 
1.2 % (w/v) of CsA could be solubilized, which was in the upper therapeutic range. 
With 10 % (w/v) of AS and ACS, respectively, it was nearly possible to reach the 
maximum applied dosing of 2 % (w/v) CsA dissolved in oil. In comparison to the 
soluble concentrations in water, this meant a 2700 fold increase of CsA and a 90 fold 
increase for budesonide [11,12]. Finally, AS and ACS solubilized four times higher 
amounts of each drug compared to Solutol and thus, showed a significantly higher 
potential as a surfactant for ophthalmic use. 
4.3.2. Micelle characterization 
4.3.2.1. Micelle size and charge 
Due to their paramount significance for the tissue intrusion micelle size and zeta 
potential were determined.  
All micelles showed very small and similar particles sizes (Fig. 4.3). AS and ACS 
formed micelles of around 10 nm, Solutol of about 12 nm. Micelle size was nearly 
unaltered after loading with CsA or budesonide, as reported in literature for drug-
loaded polymeric micelles [33,34]. Irrespective of the surfactant CsA loaded micelles 
were smaller than budesonide loaded ones or the drug-free control. All preparations 
had a narrow size distribution, with a PdI < 0.16 and, a nearly neutral zeta potential 
with no significant differences between the drug-free and drug- loaded micelles.  
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Fig. 4.3: Micelle characterization: Size, size distribution (PdI ( )) and Zeta potential of drug-loaded 
and drug-free micellar systems of Sympatens AS ( ), Sympatens ACS ( ) and Solutol ( ); the drug 
loading was 1% (w/v) CsA or 0.1 % (w/v) budesonide; *** = P < 0.001 
While on the one hand that meant that the particles would not be able to stick to the 
negatively charged tissue surface via electrostatic interactions [35]. There may be on 
the other hand a benefit on positively charged colloidal particles in terms of 
biocompatibility [17,36] 
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4.3.2.2. Shape and distribution 
To visualize the micellar structures, and to confirm the PCS results, TEM pictures 
were exemplarily taken of a 5 % Sympatens AS aqueous solution. The images are 
shown in Fig. 4.4, [A] + [B]. A homogeneous distribution of the colloidal structures 
with a size of 9.2 ± 1.2 nm could be observed. The micelles were of nearly spherical 
shape. These results agree with the data determined by dynamic light scattering and 
data by Di Tommaso et al [37].  
 
Fig. 4.4: Micelle characterization: [A]+[B] TEM images of 5 % Sympatens ACS micellar system;[A] 
overview over the homogeneous preparation; [B] single micellar structures; 
4.3.2.3. Entrapment efficiency at therapeutically dosing 
Upon the drug solubility study, the goal was now to identify the minimum amount of 
surfactant needed for therapeutically relevant aqueous formulations. Due to their 
superior solubilization potential, only Sympatens AS and ACS were investigated. 
Fig. 4.5 [A] shows the encapsulation efficiency for 0.1 % (w/v) budesonide. 
Surfactant concentrations were ranging from 0.75 % to 3.0 %. None of the 
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concentrations could encapsulate 100 % of the initial drug amount. The highest rate 
was 64 % (w/v) with 3 % AS and ACS, respectively.  
 
Fig. 4.5: Encapsulation efficacy: encapsulation of an initial amount of [A] 0.1 % (w/v) budesonide and 
[B] 0.1 % (w/v) cyclosporin A by micellar solutions of Sympatens AS ( ) and ACS ( ) at different 
concentrations; 
Due to the therapeutic doses from 0.025 % (w/v) to 0.05 % (w/v) of budesonide [32], 
surfactant concentrations between of at least 1.0 % (w/v) of AS and ACS were 
required. Similar solubilization qualities were reported by Sahib et al for a 3 % (w/v) 
PEG5000-DSPE micellar solution [14]. 
Chapter 4 
102 
 
The surfactant concentrations for cyclosporin A ranged from 0.1 % to 1.0 % (w/v) Fig. 
4.5 [B] and the initial drug amount was set to 0.1 % (w/v), according to Restasis® 
(0.05 % CsA) [38]. With at least 0.3 % (w/v) and 0.5 % (w/v) of AS and ACS, 
respectively, the encapsulation efficiency was 100 % of the initial amount of drug, but 
at 0.3 % (w/v) of ACS it was still 91 ± 7.5 %. Hence, to prepare a formulation with 
0.05 % (w/v) CsA, the amount of surfactant, could be reduced down to 0.3 % (w/v). In 
contrast, to prepare a 0.066 % CsA solution, Di Tommaso et al needed 3.0 % MPEG-
hexPLA copolymer [16]. 
4.3.3. Cornea cell compatibility 
To test the cell compatibility of formulations we used primary human epithelial cornea 
cells. Due to their sensitivity, the volume control of the cells was used as a measure 
for tolerance towards the surfactant solutions [39].  
In all cases we did not observe any adverse reaction or loss of cells in the 
monolayer. Fig. 4.6 shows the changes in cell volume for the treatment with a 5 % 
aqueous solution of Sympatens AS, a 5 % aqueous solution of ACS and a 10 % 
aqueous solution of Solutol, all compared to a 0.15 % sodium-hyaluronate solution as 
control. The cells showed a nearly constant volume decrease down to about 70 % of 
the initial cell volume for all liquids towards the endpoint of observation. Only the cell 
culture medium was tolerated without any cell volume change. Even with classical 
ringer solution a similar decrease could be detected (data not shown). Only the last 2 
values of the sample in panel [B] showed an unexpected decrease, which seemed be 
due to a layer focus problem of the camera after medium change and hence, the 
highly blurry cell membrane.  
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Fig. 4.6: Tolerability: effect towards the volume control of HCEpiC cells in-vitro as a measure of 
tolerability of the micellar solutions;  [A] 5 % (w/v) Sympatens AS ( ), [B] 5 % (w/v) Sympatens ACS  
( ) and [C] 10 % (w/v) Solutol ( ); SHS was used as control in all panels ( ); timescale: 0-300 s 
reference solution; 300-930 s switch to sample solution, 930-1500 s switch back to the control; 
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The differences between the curves of sample AS and ACS in comparison to the 
curves of the reference and Solutol were supposably detected by reason of the two 
different batches of HCEpiC cells used. Due to the fact, that the HCEpiC were 
primary cells, a higher variation between the single batches and experiments was 
expected. 
In general, it could be shown, that none of the highly concentrated surfactant 
solutions had a significantly effect on the cell volume beyond that of a commercially 
available, biocompatible, ocular lubricant. 
4.3.3.1. Drug resorption in-vitro 
 
Fig. 4.7: In-vitro resorption: amount of CsA taken up by porcine-cornea from 200µl sample solution 
over a period of 30 min; sample solutions: MS (0.05 % CsA micellar solution), Restasis® (cyclosporine 
ophthalmic emulsion 0.05 %), Oil (2 % (w/v) CsA olive oil solution); ** = P < 0.01 (t-test); 
measurements were performed in triplicate; results are shown as average ± standard errors; 
To explore the potential of our self- assembling colloidal systems to serve as a 
therapeutic formulation for the anterior eye, we investigated the CsA uptake in 
porcine corneal tissue of the 0.05 % CsA micellar solution. 
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We compared a 0.05 % micellar CsA solution to Restasis® and a 2 % CsA olive oil 
solution, which are the currently used parameters for ocular CsA administration (Fig. 
4.7). The mean drug concentration in the cornea for the MS was 
1557 ± 407 ngCsA/gcornea. It was significantly higher than those, reached with 
Restasis® (545 ± 137 ngCsA/gcornea) or the 2 % CsA oily solution 
(452 ± 142 ngCsA/gcornea). These values agree well with literature data. Daull et al. 
observed comparable levels 20 min after single administration of a cationic 0.05 % 
CsA nanoemulsion and Restasis® in rabbits [35]. Hence, even though the volume of 
200 µl, that was needed in our study to ensure a total wetting of the porcine cornea, 
was above the volume of a typically administered eye drop (25-50 µl), the in-vitro 
model seemed suitable to predict the behavior of different types of formulations quite 
well. The 2 % CsA oily solution, did not show any significant differences compared to 
Restasis®. The average concentration was even less. Despite of its high drug 
loading, which was a 40 fold of our MS and also of Restasis®, the oily solution 
showed the worst tissue levels. This, and also the significant lower levels of 
Restasis® in comparison to the 0.05 % CsA MS, seemed to be due to the expected 
partition of CsA, which is known to have a clearly higher affinity to lipophilic vehicles 
than to the hydrophilic milieu of the cornea [13]. Referring to the therapeutic tissue 
levels of CsA reported by Kaswan et al (50 – 300 ng/gtissue) [20] and the results of this 
in vitro investigation, the 0.05 % CsA MS developed by our group, should easily be 
able to cause therapeutic levels in the cornea which are significantly higher than 
those of Restasis®. In comparison to the levels of Daull and Di Tommaso et al, it 
would be possible to lower the number of applications per day towards Restasis®, 
which is at least administered twice a day [24,35,38]. Thus in combination with an 
increased therapeutic option, the 0,05 % CsA MS would enhance further the patients’ 
compliance. 
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The distribution of budesonide into the posterior segment of the eye either by topical 
or intraocular administration has to be proven in further investigations. 
4.4. Conclusion 
We summarize from the present work, our self- assembling micellar solutions are a 
highly interesting and promising approach to overcome problems, which usually 
occur with the formulation and administration of poorly water drugs. With suitable 
non-ionic surfactants the drug solubility was enhanced significantly in comparison to 
pure water. At therapeutic drug loadings only small amounts of surfactant were 
necessary to create transparent, liquid systems. The tremendous advantage of the 
AS and ACS micelles was their self assembly and drug loading directly in the 
aqueous medium by use of only gentle stirring, which led to small sized and neutrally 
charged colloidal structures, The solutions were as perfectly tolerated by HCEpiC 
cells in-vitro. Finally, for CsA, the porcine in-vitro resorption model showed big 
advantages compared to typically used and also to approved formulations. The 
mucoadhesive qualities of the PEG surface of our micelles might help to increase this 
effect further in-vivo [20].Upon these results our self- assembling micellar solutions 
are a novel option in the treatment of diseases at the anterior segment of the eye 
with poorly soluble drugs. 
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Abstract 
Colloidal, micellar systems, especially those assembled by classical surfactants are 
repeatedly reported to be challenging systems concerning their stability. With the 
present study the long term stability at 5 °C over a 12 month- period of self- 
assembling micellar solutions was investigated. The drug- free samples were 
perfectly stable in terms of micelle size and size distribution. Also no tremendous 
changes in pH and osmotic pressure, whether buffered or non-buffered, were 
observed. CsA was stable in a non-buffered solution. Constant particle size (ZAV = 
7.7 – 8.6 nm) and distribution (PdI <0.07) as well as a quite stable pH with a variation 
within one unit were detected. No loss of CsA was observed for 12 months. 
Budesonide, with a stability optimum at a slightly acid pH, showed in two of the non-
buffered systems a loss of 13 % of the initial drug content. Furthermore, a slight 
increase of particle size was detected. However, when stored in isotonic buffered 
solution at pH of 6.1, only one sample showed a drug loss of 5 %. The solutions are 
a highly promising approach towards the treatment of diseases at the anterior or 
posterior segment of the eye.  
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5.1. Introduction 
Many different approaches have been developed in recent years to deliver 
hydrophobic, poorly soluble drugs to their site of action. Nano-emulsions, liposomes, 
nano-associates or micelles are just a few examples for colloidal delivery systems 
[1–5] that have been identified as a promising approach. Micelles, formed by 
amphiphilic structures above a substance specific concentration, the so called critical 
micelle concentration (CMC), are nanoparticles with a hydrophobic core and a 
hydrophilic shell [6]. Two types of micelles are prevalent in literature: so called 
polymeric micelles, formed by copolymers and surfactant micelles, formed by 
classical surfactant molecules [7,8]. Both types have the ability to form small colloidal 
structures below 200 nm and to incorporate hydrophobic drugs into their hydrophobic 
core [6]. Chauhan et al, for example, prepared surfactant micelles loaded with the 
hydrophobic ketoconazole [9], Mondon et al., reported on cyclosporin A (CsA) loaded 
polymeric micelles [5]. However, it was claimed that polymeric micelles have a 
superior stability compared to surfactant micelles [10,11]. 
In this thesis a colloidal system with a high drug loading for the poorly soluble drugs 
budesonide (14 µg/ml [12]) and cyclosporin A (6.6 µg/ml [13]) was developed. Non-
ionic surfactants of the poly(ethylene glycol) fatty alcohol ether type were used to 
prepare micellar solutions with a particle size of 8 to 10 nm. A very important topic 
with respect to a drug product is the stability of such formulations [14]. According to 
the International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH), the purpose of stability testing 
is to provide evidence on how the quality of a drug substance or drug product 
changes with time under the influence of a variety of environmental factors such as 
temperature and humidity [15]. 
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Hence, upon the very promising data already shown in this thesis, the aim of the 
present research was to investigate the stability of drug- loaded surfactant micelles in 
terms of shelf life, particle size and residual drug content in a long term stability study 
according to the ICH guidelines for “Drug substances intended for storage in a 
refrigerator” at 5°C ± 3°C over 12 months [15]. 
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5.2. Materials and methods 
5.2.1. Materials 
Cyclosporin A (98.5 %) (CsA) was obtained from Dr. Ehrenstorfer GmbH (Augsburg, 
Germany). Budesonide (99.7 %) was purchased at the European Directorate for the 
Quality of Medicines and Healthcare (Strasbourg, France). Sympatens AS/200G (AS) 
and Sympatens ACS/200G (ACS) were kindly provided by KOLB (Hedingen, 
Switzerland). Water for injection in bulk was obtained according to the European 
Pharmacopeia by an in-house purification system (Stulln, Germany). 
Disodiumhydrogenphosphate (99.5 %), sodiumchloride (99.8 %) and phosphoric acid 
(89 %) were purchased at Merck (Darmstadt, Germany). Methanol (MeOH), 
acetonitrile (MeCN), isopropanol (all HPLC grade) and trifluoric acid (99.9 %) were 
obtained from Merck (Darmstadt, Germany).  
5.2.2. Sample preparation 
The clear and colorless micellar solutions were prepared by dissolving the drug 
and / or the surfactant in water under gentle stirring for 24 h. The different 
compositions are shown in Tab. 5.1. Besides placebo solutions, three different drug 
concentrations were made: a placebo, a low concentration and a high concentration. 
Furthermore, the two surfactants AS and ACS were investigated. Budesonide 
samples were prepared non-buffered as well as buffered. CsA samples were only 
produced non-buffered. 
Budesonide: An amount of 100 g stock solution was prepared by dissolving 5 g of 
surfactant together with 0 mg, 50 mg and 100 mg budesonide, respectively, in water. 
50 g of each solution were buffered with 52 mg disodiumhydrogenphosphate, 
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isotonized with 360 mg of sodium chloride and the pH was adjusted to 6.0 using 
phosphoric acid. Each solution, the non-buffered and the buffered one, was filled into 
15 poly(ethylene) eye drop bottles (2 ml).  
Cyclosporin A: An amount of 50 g stock solution was prepared by dissolving 2.5 g of 
surfactant together with 0 mg, 100 mg and 500 mg CsA, respectively, in water. The 
solutions were filled into 15 poly(ethylene) eye drop bottles (2 ml). 
Tab. 5.1: Sample composition: micellar solutions of budesonide and cyclosporin A for stability storage 
over 12 months using two different surfactants (s) and two different drug (d) concentrations; 
budesonide samples were prepared non-buffered (n.b.) and buffered (b.) with 
disodiumhydrogenphosphate; buffered samples were further isotonized (i.) with sodiumchloride; 
  Budesonide  Cyclosporin A 
# Surfactant c(d) / % c(s) / %   c(d) / % c(s) / %  
1 AS 0 5 n.b.     
2 AS 0.05 5 n.b.     
3 AS 0.1 5 n.b.     
4 ACS 0 5 n.b.     
5 ACS 0.05 5 n.b.     
6 ACS 0.1 5 n.b.     
7 AS     0 5 n.b. 
8 AS     0.2 5 n.b. 
9 AS     1.0 5 n.b. 
10 ACS     0 5 n.b. 
11 ACS     0.2 5 n.b. 
12 ACS     1.0 5 n.b. 
13 AS 0 5 b./i.     
14 AS 0.05 5 b./i.     
15 AS 0.1 5 b./i.     
16 ACS 0 5 b./i.     
17 ACS 0.05 5 b./i.     
18 ACS 0.1 5 b./i.     
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5.2.3. Storage conditions and sample treatment 
The samples were stored under exclusion of light over a period of 12 months at 4 °C. 
The sampling points were set to 0, 1, 3, 6, 9 and 12 months. At each point 3 bottles 
were withdrawn for analysis and equilibrated to room temperature for 24 h. One 
bottle was used for particle size measurements. The two other bottles were 
combined and pH and tonicity were assessed. Afterwards the samples were 
prepared for high performance liquid chromatography (HPLC) analysis. 
5.2.4. Physicochemical characterization  
The pH of the samples was measured at room temperature using a SevenMultiTM pH 
meter with a sampling volume of 2 ml from Mettler-Toledo GmbH (Gießen, 
Germany). The osmotic pressure was determined using a Knauer – semi-micro 
osmometer K7400 (KNAUER Wissenschaftliche Gerätebau Dr. Ing. Herbert Knauer 
GmbH, Berlin). The sample volume was 150 µl. 
5.2.5. Chromatographic analysis 
The residual amount of drug was determined using the Hitachi LaChrome Elite 
chromatographic equipment, which consisted of the HTA L-2130A pump, the HTA L-
2200 autoinjector, the HTA L-2300 column oven and the HTA L-2400 UV detector. If 
the samples were opaque they were filtered before analysis using a Durapore 
syringe filter with a pore size of 0.2 µm (Millipore Corporation, Billerica, MA, USA). 
For the budesonide analytics as solid phase a reversed phase octadecyl column 
YMC-Pack ODS-AQ, 3µm, 150 x 4.6 mm was used. The mobile phase consisted of 
(A) 65 % “buffer solution pH 3.2” and (B) 35 % acetonitrile. To obtain (A) 7.2 g 
disodiumhydrogenphosphate were dissolved in 1800 ml water. 200 ml of an aqueous 
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solution of 2.5 g/l phosphoric acid were added to these mixtures. After pH adjustment 
the solution was filtered through a 0.2 µm membrane. After 22 min a gradient over 
5 min to 50 % (A) and 50 % (B) was applied and these levels were kept till the end of 
observations at 40 min. Afterwards the column was equilibrated over 10 min to obtain 
the starting conditions. Budesonide was detected at 240 nm using UV detection. The 
flow was set to 1.6 ml/min, the injected volume was 20 µl and the column 
temperature was set to 60°C. As reference solution 25 mg budesonide was dissolved 
in 15 ml (B) and diluted to 100 ml with (A) to obtain a drug concentration of 
0.25 mg/ml. 1 ml sample solution was diluted to 2 ml with (A). Reference and 
samples were prepared in duplicate.  
For the cyclosporin A analytics as solid phase a reversed phase octadecyl column 
Waters SunFire C18, 3.5µm, 100 x 3 mm was used. The mobile phase consisted of 
(A) 38 % H2O, (B) 60 % acetonitrile and (C) 2 % isopropanol, each containing 0.01 % 
trifluoroacetic acid. A gradient was applied. Until 6.5 min the concentrations changed 
to 24 / 67 / 9 % (A / B / C). Within the next 0.5 min the amounts changed further to 25 
/ 70 / 5 % (A / B / C). These levels were kept till 9 min. Afterwards, the column was 
re-equilibrated over 6 min. CsA was detected at 220 nm using UV detection. The flow 
was set to 1.0 ml/min, the injected volume was 20 µl and the column temperature 
was set to 60°C. As reference solution (S1) 50 mg CsA were dissolved in 50 ml 
MeOH to obtain a drug concentration of 1.0 mg/ml. To obtain (S2) and (S3) 1 ml of 
(S1) was diluted to 10 ml and 100 ml with MeOH, respectively. 1 ml sample solution 
was diluted to 10 ml with MeOH. Reference and samples were prepared in duplicate. 
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5.2.6. Particle size and distribution  
The particle size of the self- assembling micelles, was measured by dynamic light 
scattering (DLS) using a Zetasizer Nano ZS (Malvern, Herrenberg, Germany). The 
hydrodynamic diameter (ZAV), the polydispersity index (PdI), the intensity weighted 
diameter (dI) and the amount of micelles at the given dI (% dI) were assessed.  The 
sample volume in the poly styrene semi-micro cuvettes was 400 µl. The 
measurements were performed in triplicate.  
5.3. Results and discussion 
5.3.1. Physicochemical characteristics  
As basic stability parameters the pH and the osmotic pressure were investigated at 
each sampling time. The non-buffered budesonide samples (Fig. 5., left panel) 
showed a quite stable pH with a small variation within one pH unit. Initially, the 
samples prepared with AS (#1-3) had a slightly lower pH than the samples prepared 
with ACS (#4-6) (Tab. 5.2). After 12 months the pH ranged between 7.5 and 5.6. 
However, there was neither a clear dependency observed in terms of the used drug 
or surfactant concentration nor in terms of the surfactant type. The samples #13-18 
(Fig. 5., right panel), buffered with disodiumhydrogenphosphate, showed a constant 
pH throughout the whole period without any significant variation. As reported in 
literature budesonide had its stability optimum in the acidic range (pH 4 – 5) and 
higher levels would lead to degradation [16]. Therefore, the buffered samples were 
adjusted to pH = 6.1 to have a milieu which would be tolerated by budesonide as well 
as by the anterior eye (pH of the tearfilm: 7.1-7.6 [17]). Due to the presence of 
bicarbonate ions in the tear film and hence, its buffer capacity, the European 
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Pharmacopeia (Pharm. Eur. 6.0) allows the application of euhydric liquids [18]. Thus, 
even with the non-buffered samples, the pH was always in an acceptable range. 
 
Fig. 5.1: Physicochemical stability: pH over 12 months of budesonide micellar solutions; left panel: 
samples # 1-6, non-buffered; right panel: samples #13-18, buffered; 
The samples #1-6 were neither buffered nor isotonized. They showed a very low, but 
constant osmotic pressure over the 12 months (Fig. 5.2, left panel). The osmotic 
pressure of the samples #13-18 was adjusted with sodium chloride and was constant 
throughout the experiment in a range around 280 mosmol. Despite the same 
treatment, only sample # 16 showed constantly higher values (Fig. 5.2, right panel). 
As a mean osmolarity in human tears, William et. al observed 318 mosmol in his 
study on 324 tear samples [19]. Even if it was shown that slightly hypotonic eye 
drops would have no disadvantage compared to isotonic solutions with dry eye 
patients [20], for stronger hypotonic conditions a swelling of cells and even an 
occurring opacity can be expected [21,22]. Therefore, it will be necessary to adjust at 
least the osmotic pressure to physiological levels to guaranty an application without 
any irritations. 
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Fig. 5.2: Physicochemical stability: osmotic pressure (π) over 12 months of budesonide micellar 
solutions; left panel: samples # 1-6, non-buffered; right panel: samples #13-18, buffered; 
Due to a known instability with ionic additives, the CsA micellar solutions (#7-12) 
were only investigated non-buffered and non-isotonized [23]. Similar to budesonide, 
their pH (Fig. 5.3, left panel) was quite constant over the time of observation. Initially 
the values were around pH 7 and decreased over 12 months to levels between pH 5 
and 7. The decrease after one month seemed to be due to a measurement problem 
because it affected all samples. A pH < 5.8 or > 11.4 is known to cause irritations 
with a possibility of 99 % [24]. However, many drugs are used in solutions with a pH 
around 5. Hence, the final pH of a solution should be a compromise between the 
stability or functional optimum of the drug and the physiological needs of an 
application. Due to the fact that CsA is known to be stable over a wide range of 
experimental conditions [25], it would be beneficial to adjust the pH of the 
subsequent formulations more in the range of the physiological pH. 
The osmotic pressure of the samples #7-12, as seen for budesonide, was very low 
but constant (Fig. 5.3, right panel). As discussed above, an adjustment to isotonic 
levels using, for example, mannitol as non-ionic additive would be preferable. 
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Fig. 5.3: Physicochemical stability: CsA micellar solutions, samples #7-12, non- buffered; left panel: 
pH; right: panel: osmotic pressure (π); 
5.3.2. Particle size and distribution 
The particle size of the micelles was determined to observe agglomeration or micelle 
growth over time. Fig. 5.4 shows the ZAV and PdI (upper panel) as well as the dI %dI 
(lower panel) for the budesonide micellar solutions (#1-6). In general, a very constant 
size of the colloidal structures was observed. The ZAV for all samples was between 
8.4 nm and 10.1 nm over the whole period. Even if there were differences detectable, 
at the end of observation all samples showed a very similar and very small ZAV. Even 
though the PdI which is a measure for the homogeneity of the size distribution 
increased slightly over time, it still was below 0.25. At the end of observation a slight 
increase of the ZAV (< 9.5 nm) and PdI (< 0,25) was observed for the non-buffered 
drug- loaded samples (#2, #3, #5). Overall, the samples prepared with ACS (#4-6), 
contained smaller micelles than samples prepared with AS (#1-3). 
For the intensity weighted diameter and its distribution similar results were observed. 
In contrast to the ZAV, the dI could show that the general size of the micelles was 
stable throughout the period of 12 months. The increased ZAV and PdI correlated with 
a decrease of the %dI at 9 and 12 months. While the dI was stable, its amount at the 
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end of observation was slightly decreased; however, at least 95 % of the micelles in 
every sample were stable. 
 
Fig. 5.4: Micelle stability: size and size distribution of the non- buffered budesonide samples #1-6; 
upper panel: hydrodynamic diameter (ZAV) and polydispersity index (PdI); lower panel: intensity 
weighted diameter (dI) and amount of micelles with the given dI (dI / %); 
Fig. 5.5 shows the results of the particle size measurement of the CsA micellar 
solutions (#7-12). Each sample had a perfectly stable ZAV and PdI over 12 months. 
The ZAV was between 7.6 nm and 8.9 nm and the PdI was < 0.1, reflecting a very 
homogeneous size distribution. At higher drug loading slightly smaller micelles were 
observed. As already seen for budesonide, the micelles prepared with AS were 
slightly larger than the ones prepared with ACS. The dI, as already seen for the ZAV, 
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was constant over the period of observation. The small PdI values from the upper 
panel were confirmed by the %dI. 
 
Fig. 5.5: Micelle stability: size and size distribution of the non- buffered CsA samples #7-12; upper 
panel: hydrodynamic diameter (ZAV) and polydispersity index (PdI); lower panel: intensity weighted 
diameter (dI) and amount of micelles with the given dI (dI / %); 
An important parameter closely related to the stability of micelles is their critical 
micelle concentration [10, 26]. As shown in this thesis, both surfactants have very low 
CMCs that seemed to be small enough, to solubilize the systems for at least one 
year [27]. Despite the fact, that the stability of micelles typically increases, when 
loaded with hydrophobic drugs [10, 26], this was not observed for CsA or 
budesonide. This may be due to the very stable drug- free micelles. In contrast, for 
budesonide few slightly larger micelles or aggregates thereof occurred. In 
comparison to already reported stability data where at 4°C with CsA loaded micelles 
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bigger particles in a size of 150 - 220 nm were detected, our micellar system seemed 
very stable [5]. We observed that the micelles loaded with budesonide did not differ 
in size from the drug- free ones. Incorporation of CsA led even to smaller micelles 
with increasing drug load. This proved as already shown in this thesis [27] that the 
micelle size seemed to be dependent on the encapsulated drug. On the one hand 
Mondon et al. as well as Elsahaby et al reported no variations for the size of their 
micelles, whether loaded or not [5,28]. On the other hand Dane et al showed an 
increase in size of their micellar system when loaded with mometasone, but also a 
decrease with tacrolimus and rapamycin [29].  
Hence, in terms of size and size distribution at 5°C we could observe a very stable 
micellar system. This would have a tremendous impact towards consistent 
characteristics regarding the behavior and resorption at the site of application. 
5.3.3. Drug content 
As a final and perhaps most important parameter of the stability study, the solubilized 
amount of drug at 5°C over time was monitored. The results were obtained using 
HPLC-MS. Fig. 5.6 shows the residual content of budesonide in the non-buffered (left 
panel) and buffered (right panel) samples. The non-buffered preparations made with 
AS (#2, 3) were quite stable over 6 months, but decreased to 87 % and 88 %, 
thereafter. However, the samples prepared with ACS (#5, 6) ended up after 12 
months with drug amounts of 100 % and 97 %, respectively. For the samples #2 and 
#3 it seemed that the decrease of the budesonide concentration correlated with the 
simultaneously decreasing %dI (Tab. 5.2), however, sample #5 also showed this 
decrease in %dI without any loss of drug. 
Chapter 5 
126 
 
The buffered samples (#14, #15, #17, #18) were all perfectly stable over 12 months. 
In comparison to the non-buffered samples the buffered ones showed clearly less 
variation of drug content over time. It seemed that the more stable pH conditions led 
to more consistent concentrations. 
 
Fig. 5.6: Drug content: residual drug amount of budesonide at 5°C over a period of 12 months; left 
panel: samples #1-6, non- buffered; right panel: samples #13-18, buffered; 
The residual drug concentration of CsA was monitored only in non-buffered and non-
isotonized formulations, due to known incompatibilities with ionic additives (Fig. 5.7) 
[23]. As CsA was found to be stable under various experimental conditions [25], none 
of the slightly acid to neutral environments showed a significant impact on drug 
stability. Further, there was no dependency observed on the surfactants used for 
preparation. All formulations showed perfectly stable drug concentrations over 12 
months at 5°C. A summarizing overview on the results is given in Tab. 5.2. 
As reported also by other groups, colloidal, micellar systems, but preferably 
polymeric micellar systems were observed to be stable formulations for poorly 
soluble drugs when stored under suitable conditions. Polymeric micelles formed by a 
copolymer of methoxy poly(ethylene glycol) and hexyl – substituted - polylactide, 
loaded with CsA, stored at 4°C over 12 months showed a drug loss of less than 7 % 
[5]. Also stored at 4°C the mixed micelles of Wang et al solubilized paclitaxel over 6 
   5.3. Results and discussion 
127 
 
months with a final loss of 2.9 % drug [30]. Further, propofol could be prepared as a 
stable formulation at 25°C over 6 months with mPEG-PLA/Solutol mixed micelles by 
use of polymeric and surfactant components [31]. Without a perfectly fitting surfactant 
or combinations thereof micellar systems were shown to lose their dissolved 
hydrophobic drug much earlier [32]. 
 
Fig. 5.7: Drug content: residual drug amount of CsA at 5°C over a period of 12 months; samples #7-
12, non- buffered; 
In comparison and as expected, budesonide showed better stability characteristics in 
buffered solution while CsA was found to be stable in non-buffered formulations. Only 
two samples at all fell slightly below the critical 90% mark of drug content after 12 
months. Based on these results, further investigations using sterile sample 
preparations, the adjustment of the tonicity with Mannitol of the CsA solutions, and 
temperature levels of 5°C, 25°C and 40°C need to be conducted in the future. 
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Tab. 5.2: Result overview: summary and comparison of the values at the beginning (o) and the end (12) 
of the stability study; samples #1-6: budesonide micellar solutions, non- buffered; samples #7-12: CsA 
micellar solutions, non- buffered; samples #13-18: budesonide micellar solutions, buffered; the grey 
shaded lines mark the samples with a final drug amount below 90 %; n.d. = not determined; 
# pHo pH12 πo π12 ZAVo ZAV12 PdIo PdI12 dIo dI12 %dIo %dI12 c(d)o c(d)12 
   mosmol nm   nm % % 
1 5.8 6.7 1 4 8.7 8.8 0.08 0.05 9.4 9.4 100 100 - - 
2 5.9 5.9 0 7 8.7 9.4 0.02 0.21 9.1 9.4 100 96.8 100 87 
3 6.0 6.6 1 5 8.7 9.5 0.04 0.14 9.2 9.2 100 95.3 100 88 
4 7.2 6.4 4 4 8.5 8.6 0.03 0.07 8.9 9.2 100 100 - - 
5 6.8 7.5 12 4 8.5 9.2 0.02 0.24 8.9 8.9 100 94.8 100 100 
6 6.8 5.6 8 5 8.4 8.5 0.04 0.05 8.9 9.1 100 100 100 97 
7 7.0 5.0 4 4 8.7 8.7 0.04 0.06 9.3 9.3 100 100   
8 7.5 6.3 3 7 8.5 8.6 0.02 0.06 8.2 8.4 100 100 100 103 
9 6.8 6.0 7 6 7.8 7.8 0.03 0.06 8.9 9.2 100 100 100 106 
10 7.1 6.5 5 3 8.4 8.3 0.02 0.02 8.8 8.8 100 100   
11 7.1 7.1 4 7 8.3 8.4 0.03 0.08 8.1 8.2 100 100 100 102 
12 7.1 5.5 1 5 7.7 7.7 0.03 0.05 8.7 9.1 100 100 100 103 
13 6.1 6.0 276 285 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. - - 
14 6.1 6.1 269 289 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 100 100 
15 6.1 6.1 286 277 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 100 95 
16 6.1 6.0 326 325 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. - - 
17 6.1 6.0 287 295 n.d n.d. n.d. n.d. n.d. n.d. n.d. n.d. 100 100 
18 6.1 6.0 280 280 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 100 100 
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5.4. Conclusion 
With the present work a self- assembling colloidal micellar system was investigated 
in terms of its stability at 5 °C over a 12 months period. For budesonide, and 
cyclosporin A suitable conditions for stable surfactant micelles were found. 
Depending on the incorporated drug, either a buffered or non-buffered environment 
was necessary. The solutions were stable in terms of size and size distribution as 
well as in their residual drug content. None of the stable formulations decreased to a 
final drug concentration below 95 % after 12 months. Based on these results further 
optimization and stability studies according to the ICH Guidelines at 25°C / 65 % RH 
and 40°C / 70 % RH have to be done. With the present long term stability study the 
hypothesis could be supported that the self- assembling surfactant micelles for the 
application of poorly soluble drugs are a very promising approach towards the 
treatment of for example inflammatory diseases at the anterior eye. 
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Abstract 
For highly potent but poorly soluble drugs like cyclosporine A, the development of 
formulations providing an increase of corneal drug tissue levels and thus of 
bioavailability, in combination with a rise of patient compliance is still a challenge. 
Therefore, we designed two liquid application systems, an in-situ nanosuspension 
(INS) and a micellar solution (MS) and tested both formulations in vivo on rabbits 
regarding their tolerability and the tissue uptake of CsA. The INS evoked minimal to 
no irritations. The MS on the other hand, was perfectly tolerated. After an observation 
period of 180 min, the rabbits were sacrificed and the corneal tissue levels of CsA 
were analyzed. The INS and the MS both showed high levels of 
1683 ± 430 ngCsA / gcornea and 826 ± 163 ngCsA / gcornea, respectively, and exceeded 
drug tissue levels reported for Restasis® (350 ngCsA / gcornea) and cationic emulsions 
(750 ngCsA / gcornea). Furthermore, the data correlated well with in-vitro studies using 
porcine eyes. Upon these results our INS and MS marked outstanding novel 
approaches for the treatment of inflammatory ophthalmic diseases. 
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6.1. Introduction 
The cyclic undecapeptide cyclosporin A (CsA) shows pharmacological activities, that 
makes it most attractive for a number of ophthalmic applications [1]. As a potent 
immunosuppressant, it is widely used to prevent corneal graft rejection and to fight 
diseases involving pre-inflammatory cytokines, like dry eye disease (DED) or 
autoimmune uveitis [2,3]. For DED the mechanism of CsA action has not been 
completely unraveled, but it seems to be related to its immune-modulatory activity, 
which decreases local inflammation [4].  
Due to the fact, that CsA is a highly lipophilic and poorly water soluble compound 
(6.6 µg/ml [5]; logP = 3 [6]), it is frequently administered as an oily solution. 
Unfortunately, such preparations are poorly tolerated and lead to low bioavailability 
because of higher attraction of the drug by the lipophilic vehicle, rather than the more 
hydrophilic tissue [6–10]. However, as known from the literature, therapeutic tissue 
levels have to be at least 50 – 300 ngCsA/gcornea [11]. After one week with five 
instillations per day in-vivo tissue levels of approximately 500 ngCsA/gcornea have been 
reached [12]. This suggests that therapeutic tissue levels are just reach at the 
expense of a large number of instillations and, therefore, questionable patient 
compliance. The first and only US Food and Drug Administration (FDA) approved 
product Restasis®, a 0.05 % CsA emulsion, did not increase the CsA concentrations 
in corneal tissue. In contrary, after twice a day administration over one week Di 
Tommaso et al showed levels below the limit of quantification (LOQ = 2 ng/ml) [13], 
while Daull et al detected approximately 350 ngCsA/gcornea [14] 3 hours after a single 
instillation of 50 µl Restasis®.  
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It is therefore, little surprising that more recently polymeric micelles [13,15] and 
cationic emulsions [14] emerged as promising options for the ocular CsA delivery 
with significantly increased tissue levels after single and also multiple dosing in-vivo. 
Unfortunately, some of these formulations still come with problems like a 
cumbersome manufacturing or unclear tolerability and toxicity over a midterm or 
long-term period [15–18]. To overcome these problems, our group developed two 
novel ophthalmic CsA delivery systems based on simple manufacturing and well 
known ingredients only. An in-situ forming nanosuspension (INS) made of liquid 
poly(ethylene glycols) (PEG) that avoid the disadvantages of lipophilic solvents [19], 
and on the other hand a simple micellar solution (MS) containing non ionic 
surfactants that increase drug solubility [20]. Both formulations were already shown 
to have a tremendous potential to increase CsA resorption in-vitro [19,20]. The aim of 
the current study was to investigate the INS and our MS in terms of biocompatibility 
and bioavailability in corneal tissue in-vivo. 
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6.2. Materials and methods 
6.2.1. Materials 
Cyclosporin A (98.5 %) (CsA) was obtained from Dr. Ehrenstorfer GmbH (Augsburg, 
Germany). Cyclosporin D (CsD) was a kind gift of Prof. Dr. F. Kees (University of 
Regensburg, Regensburg). Sympatens AS/200G (AS) was kindly provided by KOLB 
(Hedingen, Switzerland). Solutol® HS 15 was a kind gift from the BASF 
(Ludwigshafen, Germany). Polyglycol DME500, a dimethoxy-poly(ethylene glycol) 
(MW = 500 g/mol), was supplied by Clariant Produkte (Deutschland) GmbH (Frankfurt 
a. M., Germany). Mannitol was purchased from Caesar & Loretz GmbH (Hilden, 
Germany). Deionized water was obtained from a Milli-Q	   water purification system 
from Millipore (Schwalbach, Germany). Methanol (MeOH) (HPLC grade) was 
purchased from Merck (Darmstadt, Germany). Fumaric acid (FA), 0.1 N hydrochloric 
acid  and 0,1 N sodium hydroxide solution were obtained from Carl Roth (Karlsruhe, 
Germany). 
6.2.2. Preparation and characterization of the in-situ Nanosuspension 
In-situ nanosuspensions were prepared as liquid, transparent and colorless solutions, 
from which drug nanostructures precipitate upon contact with the aqueous tear fluid. 
Sample #1, a high concentrated INS placebo solution, was prepared of 55 % 
DME500, 13 % Solutol and 32 % water by gentle stirring over night. Sample #2, a 
low concentrated INS placebo solution, was prepared from 39 % DME500, 5 % 
Solutol and 56 % water gentle stirring over night. Sample #3, a low concentrated INS 
CsA solution was prepared in analogy from 39 % DME500, 5 % Solutol and 0.4 % 
After 24 h, 31.6 % water were added to each solution under stirring for 1 hour, which 
did not trigger precipitation but helped to reduce the content of non-aqueous solvent. 
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The pH of the samples was adjusted to 7.4 with 0.1 N hydrochloric acid using a 
Sartorius PB-11 basic pH meter equipped with a pH combination electrode PY-P11 
(Sartorius AG, Goettingen). The final solutions were sterilized using a FP 30 syringe 
filter unit containing a regenerated cellulose membrane with a pore size of 0.2 µm 
(Whatmann GmbH, Dassel, Germany). The filtered solutions were stored in sterile 
vials at 5°C until further use. 
6.2.3. Preparation and characterization of the micellar solution 
The clear and colorless self- assembling micellar solutions consisted of a non-ionic 
surfactant, drug and water. For the placebo solution (sample #4), 0.3 % Sympatens 
AS and for the drug-loaded preparation (sample #5) 0.3 % Sympatens AS and 
0.05 % cyclosporine A were dissolved with an isotonic aqueous 5.2 % mannitol 
solution under gentle stirring over night. The pH was again adjusted to 7.4 as 
described above. The tonicity was determined using a Knauer – semi micro 
osmometer K7400 (KNAUER Wissenschaftliche Gerätebau GmbH, Berlin, Germany). 
Sterile filtration and storage thereafter was under the same condition as for the INS 
solutions. 
6.2.4. Size and zeta-potential measurements 
300 µl of sample #3 were precipitated with 100 µl water under gentle mixing in an 
1.5 ml eppendorf cup. The micellar solutions were used as prepared above. The 
particle size was measured by dynamic light scattering (DLS) using a Zetasizer Nano 
ZS (Malvern, Herrenberg, Germany). The sample volume used in the polystyrene 
semi-micro cuvettes was 400 µl. The zeta potential was measured in folded capillary 
cells (Malvern, Herrenberg, Germany) with a sample volume of about 1 ml by laser 
doppler electrophoresis using again a Zetasizer Nano ZS. 
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6.2.5. Animals 
For the investigations male chinchilla-bastard rabbits, weighing 3 kg, were used. 
Before starting the experiments, the ocular surface was evaluated visually for any 
damage using a Kowa SL-15 hand slit lamp (b o n Optic Vertriebsgesellschaft mbH, 
Lübeck, Germany). The experiments were conducted exactly as outlined in the 
experimental protocol approved by the University ethics committee and the District 
Government of Upper Palatinate (reference number: 54-2532.1-21/10). 
6.2.6. Tolerability studies 
5 rabbits each were used for the investigation of the INS solutions, and for the 
micellar solutions, respectively. 
The tolerability investigation was a two step process. In a first experiment 25 µl of the 
sample #1 were instilled into the right eye and 25 µl of a sodium hyaluronate lubricant 
solution serving as negative control were instilled into the left eye of an animal. The 
eyes were evaluated visually using a hand slit lamp immediately after the application 
and 15, 30, 45, 60, 120 and 180 min thereafter. Four weeks later, the eyes were 
evaluated again prior to a second set of experiments to make sure the formulations 
had been tolerated. Then 25 µl placebo sample #2 was instilled in the left eye and 
25 µl of the drug- loaded sample #3 were instilled in the right eye of an animal. The 
eyes were again examined as outlined above. The evaluation and scoring was 
performed as described by Ballantyne B. [21]. 
Micellar solutions were characterized as shown above for the INS. Initially sample #4 
and the lubricant were instilled. Four weeks later sample #4 and #5 were used. 
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6.2.7. Drug resorption studies 
3 hours after the treatment with the drug- loaded samples, the rabbits were sacrificed 
by intravenous injection of 200 mg/kganimal pentobarbital sodium. Both eyes were 
enucleated and the cornea were excised. The harvested tissue were homogenized 
using liquid nitrogen in combination with a tissue pulverizer (made by the University 
machine shop in analogy to the Bessman Tissue Pulverizer). Each homogenized 
cornea was transferred to a glass vial and weighed. The cornea were incubated for 
2h under gentle stirring with 0.5 ml MeOH, containing 0.1 µg/ml CsD as internal 
standard. The extract was centrifuged and the supernatant stored in HPLC vials at -
80°C until analysis.  
6.2.8. Chromatographic equipment and conditions 
CsA analysis was carried out by ultra high performance liquid chromatography in 
combination with mass spectrometry (UHPLC-MS) according to Rodriguez-Aller et al 
(2011) [22]. An Agilent Technologies UHPLC system equipped with a 6540 
quadrupole time of flight (Q-TOF) LC/MS system fitted with an Agilent jet stream 
electron spray ionization (AJS ESI) interface (Agilent Technologies Deutschland 
GmbH, Böblingen, Germany) was used. The further equipment consisted of a high 
performance (HiP) autosampler G4226A with a sample volume of 2 µl, a binary pump 
G4220A and a column compartment G1316C kept at 70 °C. The AJS ESI was used 
in positive ion mode. Separation was performed on a Waters Aquity BEH c18, 1.7 u, 
2.1 x 50 mm column at a flow rate of 0,6 ml/min (Waters Corporation, Milford, MA, 
USA). The mobile phase consisted of (A) water and (B) methanol each containing 
0.1 % formic acid. A linear gradient was applied from 40 % A to 0 % A over 3 min. 
After each analysis the column was allowed to equilibrate for 3 minutes to the starting 
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conditions. The MassHunter Workstation software was used for data acquisition 
(Agilent Technologies Deutschland GmbH, Böblingen, Germany). Data handling and 
processing were done using Microsoft Excel 2007 and the Dintest 2004 software 
(ARVECON GmbH, Walldorf, Germany). 
6.2.9. Statistics 
The obtained data were analyzed using a t – test at a significance level of p < 0.05 
using SigmaPlot 11.0. 
6.3. Results and discussion 
6.3.1. Characterization of the samples 
Tab. 6.1: Sample characterization: chart of the different samples used for tolerability and resorption 
studies with male rabbits; pH, tonicity, particle size (ZAV) and zeta- potential (ZP) were determined; 
# Sample Composition  pH Osmotic pressure ZAV PdI ZP 
     mosmol nm  mV 
1 High concentrated INS - Placebo 
 
55 % DME500 
13,7 % Solutol 
32.3 % H2O 
 
 7.4 >> 3000 - - - 
2 Low concentrated INS - Placebo 
39 % DME500 
5 % Solutol 
56 % H2O 
 
 7.4 > 3000 - - - 
3 Low concentrated INS - Verum 
39 % DME500 
5 % Solutol 
55.6 % H2O 
0.4 % CsA 
 
 7.4 > 3000 385  ± 5 
0.2 ± 
0.03 
-
0.06  ±
 0.04 
4 Micellar Solution- Placebo 
0.3 % AS 
5.2 % Mannitol 
H2O ad 100 
 
 7.4 270 10.1 ± 0.03 
0.07 ± 
0.008 
-
0.4  ± 
0.1 
5 Micellar Solution- Verum 
0.3 % AS 
5.2 % Mannitol 
0.05 % CsA 
H2O ad 100 
 
 7.4 271 9.7 ± 0.05 
0.1± 
0.003 
-
0.6  ± 
0.3 
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Prior to the in-vivo experiments the solutions were characterized physicochemically. 
Tab. 6.1 shows their pH, tonicity, particle size and zeta potential. Since they are 
drug-free, no precipitation could be induced with the placebo solutions and thus 
neither particle size nor a zeta potential could be measured. After precipitation of 
sample #3 colloidal particles of 385 nm, a PdI of 0.2 ± 0.03 and a zeta- potential of –
 0.06 ± 0.04 mV were obtained. The drug-free and drug-loaded MS showed a tonicity 
of 270 mosmol and 271 mosmol, a size of 10.1 ± 0.03 nm and 9.7  ± 0.05 nm, and a 
zeta potential of – 0.4 ± 0.1 mV and – 0.6 ± 0.3 mV, respectively. The PdI was below 
0.1 for all MS. 
6.3.2. Biocompatibility of the placebo preparations 
Fig. 6.1 shows the average scoring and the standard error for five male rabbits 
treated with the high concentrated INS placebo solution (sample #1). Such a 
preparation would able to dissolve as much as 1.0 % CsA [19]. Initially, all rabbits 
showed a reddening of the conjunctiva, a moderate swelling of the lids and only few 
slightly opaque spots on the cornea. The initial total score up to 15 min was 
10.6 ± 1.6 scoring points (SP) which is a fifth of the maximum score (54 SP). The 
animals rubbed their eyes and behaved nervous, which was supposably due to a 
considerable discomfort. After 45 min only two of the rabbits still showed an effect, 
after 60 min there was only one left (1.4 ± 1.4 SP). Thus, the initial reaction was 
reversible within one hour, which is in very good agreement with the material safety 
data sheet (MSDS) of the supplier, based on OECD guideline 405 [23]. According to 
the document pure DME500 showed no irritations at the rabbits’ eye 1, 24, 48 and 
72 hours after application.  
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Fig. 6.1: Tolerability score of 5 male rabbits over a period of 180 min after instillation of a 25 µl droplet 
of the high concentrated INS placebo solution (55% DME500 / 13.7% Solutol/ 32.3% H2O); (A) cornea, 
(B) conjunctiva/lids; (C) total score; data is plotted against the maximum possible score for each 
panel; Data is shown as average with standard error (n=5); 
Due to the unfavorable tolerability of sample solution #1, four weeks later, the 
tolerability of the low concentrated INS placebo solution (sample #2), which would 
still be able to carry 0.4 % CsA was investigated to assess the benefit of the lower 
DME500 concentration (Fig. 6.2). Initially, a minimal reddening of the conjunctiva was 
observed, but in a way, that it could only be seen by use of the slit lamp. The cornea 
showed no reaction. The initial score was 1.8 ± 0,2 out of 54 SP. No eye rubbing or 
any abnormal behavior could be observed. After 15 min, only one rabbit showed a 
minimal reaction leading to a total scoring of 0.4 ± 0.4. After 30 min no further effect 
was detected. Compared to highly concentrated INS placebo solution, the low 
concentrated one showed a tremendous increase in biocompatibility.  
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Fig. 6.2: Tolerability score of 5 male rabbits over a period of 180 min after instillation of a 25 µl droplet 
of the low concentrated INS placebo ( ) and 0.4 % CsA solution ( ) (39% DME500 / 5% Solutol/ 
55.6% H2O); (A) cornea, (B) conjunctiva/lids; (C) total score; data is plotted against the maximum 
possible score for each panel; data is shown as average with standard error (n=5); 
To visualize the nearly perfect tolerability of sample #2, the eyes of the five treated 
rabbits, 15 min after instillation are shown in Fig. 6.3. The lids showed a normal, 
healthy rosy color, without any swelling. Even though a clearly hypertonic solution 
was instilled, the conjunctiva and cornea showed no signs of pathological alterations. 
Finally, the placebo MS (sample #4) was investigated (Fig. 6.4). None of the animals 
showed any kind of response. Neither the cornea, nor the conjunctiva or the lids 
showed any alteration. No behavioral reaction nor any kind of eye rubbing was 
observed. The solution was perfectly tolerated.  
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Fig. 6.3: Pictures of 5 male rabbit eyes (left eye) 15 min after treatment with 25 µl of the low 
concentrated INS 0.4 % CsA solution (39% DME500 / 5% Solutol/ 55.6% H2O); 
6.3.3. Biocompatibility of the drug- loaded preparations. 
After the placebo solutions the drug-loaded solutions (sample #3 and #5) were 
investigated (Fig. 6.2 and Fig. 6.4). No abnormalities could be detected and both 
solutions behaved exactly as the respective placebo preparation. The drug- loaded 
samples confirmed the good biocompatibility of the INS and the MS placebo 
solutions. This is in accordance with data published by di Tommaso et al, who could 
not show a significant difference between their 0.05 % CsA loaded micellar system 
and an isotonic saline solution [24]. 
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Fig. 6.4: Tolerability score of 5 male rabbits over a period of 180 min after instillation of a 25 µl droplet; 
initial instillation of the MS placebo ( ); MS placebo ( ) and MS 0.05% CsA solution ( ) after 4 
weeks; (A) cornea, (B) conjunctiva/lids; (C) total score; data is plotted against the maximum possible 
score for each panel; Data is shown as average with standard error (n=5); 
6.3.4. Bioavailability 
The most important parameter to assess was the absorbed amount of CsA in the 
cornea upon instillation. Based on the compatibility study we tested INS sample #3 
and MS sample #5. The corneal tissue levels of CsA were determined three hours 
after instillation (Fig. 6.5). For the INS (0.4 % CsA) a value of 
1683 ± 430 ngCsA / gcornea was determined. The MS (0.05 % CsA) produced tissue 
levels of 826 ± 163 ngCsA / gcornea. In the contra lateral eyes significantly  lower 
amounts of 207 ± 77 ngCsA / gcornea and 151 ± 102 ngCsA / gcornea  for the INS and the 
MS, respectively were detected. These concentrations correspond to approximately 
18 % and 12 % of the concentrations found in the treated eyes. Such significant CsA 
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levels in the contra lateral, untreated eye were first reported by Wiederholt et al 
(13 %) [25]. Vernillet et al later confirmed the passage of CsA from the treated to the 
non-treated eye [26].  
 
Fig. 6.5: Amount of CsA taken up by the rabbits’ corneal tissues; INS 0.4% CsA, INS placebo, MS 
0.05% CsA solution and MS placebo were instilled (25 µl); the left eyes of the rabbits were treated with 
the drug- loaded solutions, the right eyes with placebo; n = 5;  ** = P < 0.01 / *** = P <0.001; 
Both samples, the INS as well as the MS simply reached outstandingly high CsA 
tissue levels. The 1683 ngCsA / gcornea of the INS were significantly higher than  levels 
reached by a 0.1 % CsA cationic emulsion (1200 ngCsA / gcornea) [14]and a 0.05 % 
CsA polymeric micelle formulation after twice a day administration over one week 
(1540 ngCsA / gcornea) [13]. The 826 ngCsA / gcornea observed for the MS were 
comparable to concentrations reported for cationic emulsions containing 0.05 % CsA. 
They are known to show a longer retention at the cornea, because of their positive 
charge. Despite its neutral surface charge our micellar solution generated even 
slightly higher tissue levels than the positively charged emulsion after 3 hours (750 
ngCsA / gcornea), which was administered with a drop volume of 50 µl [14], compared to 
25 µl in this study. That neither the INS, not the MS carry positive charges on their 
surfaces, is definitely an advantage with respect to long-term compatibility [17,18]. 
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The in-vivo data for the MS and the INS solution are well in line with precious in-vitro 
studies. Using porcine eyes we found after 30 min in-vitro 3345 ± 745 ngCsA / gcornea 
for the 0.4 % CsA INS [19] and 1557 ± 407 ngCsA / gcornea for the MS [20]. This is 
exactly twice the concentrations measured in-vivo after 3 h. According to these 
results, our porcine in-vitro model seems to be highly suitable to predict corneal in-
vivo levels and thus it may help to decrease the number of in-vivo investigations on 
animals. 
The plethora of data found in the literature in conjugation with our data, allows for a 
direct comparison with Restasis® and oily formulations without any need for further 
experiments. In-vitro we could already show significant higher levels for the INS and 
the MS compared to Restasis® (0.05 % CsA emulsion) and a 2 % CsA oily solution, 
while there was no significantly difference between them [19,20]. Since the in-vitro 
model seems to be highly predictive for in-vivo tissue levels, we expect significantly 
lower concentrations for Restasis® and the oily eye drops on the rabbit eye. This is 
confirmed by the study of Daull et al who reported for a single instillation of 50 µl 
Restasis® at rabbit eyes in-vivo after 180 min tissue levels of about 350 ngCsA / gcornea 
[14]. This is only just a fifth of the levels reached by our INS with a droplet size of 
25 µl. For a 0.5 % CsA oil formulation administered five times a day over one week 
levels of only 580 ngCsA / gcornea were reached at rats in-vivo [12]. This lower 
bioavailability of CsA delivered by formulations containing an oil-phase, which is a 
perfect solvent for the highly lipophilic drug, seemed to be due to the higher affinity of 
the CsA to the oily vehicle, than to the hydrophilic environment of the corneal tissue 
[27,28]. We could overcome these problems with our preparations, which are rather 
simple in manufacturing. They offer an option to decrease the number of instillations 
per day and thus, improve patient compliance. 
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6.4. Conclusion 
The INS and the MS are both preparations with a high therapeutic potential. With no 
irritations at all, the MS marked the perfect system for an application at the anterior 
eye. Also for the INS only a minimal initial reaction was observed. Finally, both 
formulations were capable to reach very high drug levels in corneal tissue. Besides 
the outstanding tissue levels, the formulations offer big advantages regarding simple 
manufacturing from only well known compounds. Hence, both novel delivery systems 
mark highly promising approaches for the efficient treatment of inflammatory 
ophthalmic diseases and may help to increase the patient compliance by lowering 
the number of instillations per day. 
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This thesis was focused on the development of efficient novel liquid formulations for 
poorly water soluble drugs for the treatment of inflammatory ophthalmic diseases. 
With Restasis® there is currently only one drug product approved by the FDA, in the 
US only, for the treatment of dry eye syndrome. It still suffers from low bioavailability, 
bad biocompatibility and thus a low patient compliance, as well as cumbersome 
manufacturing. Hence, there is a tremendous lack in the options for a causal therapy 
(Chapter 1). For this reason, two novel approaches, which could be finally prepared 
at room temperature only by gentle stirring from well known compounds, were 
investigated; an in-situ nanosuspension (INS), a clear solution which precipitates into 
nanoparticles upon contact with the tear fluid, and self- assembling micellar solution 
(MS) consisting of suitable no-ionic surfactants, water and drug only. 
Initially, a selection of poly(ethylene glycol)-based solvents was investigated in terms 
of their ability to solubilize the lipophilic drugs cyclosporin A, budesonide and 
beclometasone as well as different viscosity enhancing or surface active additives 
(Chapter 2). The solvents showed outstanding solubilizing qualities for the drugs and 
the non-ionic surfactant Solutol® HS15 and further good compatibility with polymers. 
A turbidimetric high throughput method to determine the exact concentrations of 
water, at which a precipitation occurred, could be established. Thereby, with all 
solvents the concept of an in-situ precipitating formulation could be proven, with 
unique characteristics for each formulation. Unfortunately, in combination with 
budesonide and beclometasone it was not possible to vary or even control the 
precipitation. In presence of Solutol no further precipitation occurred. However, this 
made Solutol a promising candidate for development of micellar solutions (Chapter 
4). As budesonide and beclometasone were not suitable for further INS 
investigations, they were exclusively conducted with cyclosporin A. 
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Upon this basic characterization study and the proof of the INS concept, a defined 
INS system containing CsA could be prepared and investigated with the solvent 
DME500, a poly(ethylene glycol) ether with an average molecular mass of 500 Da 
(Chapter 3). It was possible to control the amount of water necessary for a 
precipitation as well as the size of the resulting nanoparticles. The formulation used 
for biocompatibility and bioavailability studies showed a particle size of 697 ± 19 nm, 
a polydispersity index (PdI) of 0.1 ± 0.05. The particles carried no surface charge. By 
use of a flow through cell culture system in combination with a microscope equipped 
with a camera, the change in cell volume of primary human epithelia cornea cells 
(HCEpiC) by contact with the formulations was used as a measure for 
biocompatibility, and was found to be as good as a commercial aqueous solution of 
sodium hyaluronate. The study on drug uptake into porcine cornea was performed 
using custom made glass resorption chambers (CRC). Outstanding high tissue levels 
of cyclosporin A (3345 ngCsA/gcornea) which significantly exceeded those of Restasis® 
(545 ngCsA/gcornea) and an oily CsA solution (452 ngCsA/gcornea) were detected. To this 
end, the INS concept was shown to be functionally, biocompatible and able to reach 
high drug tissue levels in-vitro. 
The second approach investigated and developed in this thesis was a self- 
assembling micellar solution. To reach this goal, by sorting of different non-ionic 
surfactants, Sympatens AS and Sympatens ACS, two poly(ethylene glycol) fat-
alcohol ethers, were observed to be most suitable, due to their high efficiency in 
terms of drug loading (Chapter 4) and stability (Chapter 5). Only very low 
concentrations were necessary to reach therapeutic drug loadings for budesonide 
and cyclosporin A. The non-charged micelles had depending on their drug load a 
size from 8 to 10 nm and a monomodal size distribution (PdI < 0.1). They were 
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perfectly tolerated by the established HCEpiC model in-vitro and a first preclinical 
formulation with 0.05 CsA and 0.3 % Sympatens AS reached significantly higher in-
vitro drug tissue levels (1557 ngCsA/gcornea) in porcine cornea than Restasis® 
(545 ngCsA/gcornea) and an oily solution of CsA (452 ngCsA/gcornea) (Chapter 4). 
Furthermore, conditions could be achieved for non-loaded as well as drug-loaded 
systems at which the micellar system could be proven to be stable over a period of at 
least 12 months at 5 °C (Chapter 5). 
With the last study, shown in Chapter 6, the two novel application systems were 
investigated for their compatibility and efficiency in-vivo. This allowed concomitantly 
to investigate the significance of the porcine in-vitro model. Both formulations, the 
INS and the MS, were well tolerated by the rabbits. With no abnormal reaction at all, 
the MS marked the perfect system and even exceeded the INS which caused only a 
minimal initial irritation. The tissue levels reached by the INS and the MS after 3 h 
were outstandingly high and exactly half of the levels detected for both formulations 
with the in-vitro model after 30 min. Furthermore, the in-vivo concentrations were 
significantly higher than those of Restasis® and a cationic emulsion with charge 
prolonged cornea retention.  
In summary, it can be said that the INS and the MS could be shown to be 
formulations with simple manufacturing, high stability and biocompatibility. Both 
reached outstanding drug tissue levels. The established porcine in-vitro model turned 
out to reliably predict in-vivo drug cornea levels and thus, avoid unnecessary animal 
experiments. Both liquid application systems for poorly soluble drugs could be 
developed up to a pre-clinical form which are ready to enter clinical tests as new drug 
products for the causal treatment of inflammatory ophthalmic diseases such as the 
dry eye syndrome. 
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Abbreviations 
ACS ...................... Sympatens ACS / 200 G 
ARMD .................. age related macular degeneration 
AS ........................ Sympatens AS / 200 G 
b.i. ........................ buffered and isotonized 
BEC ...................... beclometasone 
BUD ..................... budesonide 
CA ........................ cellulose acetate 
CEpiCM ................ corneal epithelial cell medium 
CL ........................ contact lens 
CMC ..................... critical micelle concentration 
CO ........................ cylindrical opening 
CRC ..................... custom made glass resorption chamber 
CsA ...................... cyclosporin A 
CsD ...................... cyclosporin D 
DED ..................... dry eye disease 
dI .......................... intensity weighted diameter 
DLS ...................... dynamic light scattering 
DME ..................... di-methoxy-poly(ethylene glycol) 
eSEM ................... environmental scanning electron microscopy 
ESI ....................... electron spray ionization 
FDA ...................... U.S. Food and Drug Administration 
HCEpiC ................ primary human corneal epithelial cells 
HCl ....................... hydrochloric acid 
HPLC ................... high pressure liquid chromatography 
ICH ....................... International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use 
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IL .......................... interleukin 
INS ....................... in-situ nanosuspension 
KCS ...................... keratoconjunctivitis sicca 
LFU ...................... lacrimal functional unit 
LOD ...................... limit of detection 
Log P .................... octanol water coefficient 
LOQ ..................... limit of quantification 
M .......................... mono-methoxy-poly(ethylene glycol) 
MAPK ................... mitogen-activated protein kinase 
MAS ..................... mannitol aqueous solution 
MeCN ................... acetonitrile 
MeOH ................... methanol 
MGD ..................... meibomian gland dysfunction 
MMP ..................... matrix metalloproteinase 
MPEG .................. mono-methoxy-poly(ethylene glycol) 
MS ........................ mass spectroscopy 
MS ........................ micellar solution 
MSDS ................... material safety data sheet 
MW ........................ molar weight 
n.b. ....................... non-buffered 
NaOH ................... sodium hydroxide 
NFAT .................... nuclear factor of activated T-lymphocytes 
NFκB .................... nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
NR ........................ nile red 
NSSDE ................. non-Sjogrens syndrome dry eye 
OS ........................ other solubilizing agent 
PA ........................ polyamide 
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PCS ...................... photon correlation spectroscopy 
PdI ........................ polydispersity index 
PE ........................ polyethylene 
PEG ..................... poly(ethylene glycol) 
PEI ....................... polyethylenimine 
PLA ...................... polylactide 
PoP ...................... point of precipitation 
PP ........................ polypropylene 
Q-TOF .................. quadrupole time of flight 
RC ........................ regenerated cellulose 
RM ANOVA .......... repeated measurements analysis of variance 
SEM ..................... scanning electron microscopy 
SHS ...................... sodium hyaluronate solution 
SL ......................... stock solution 
SP ........................ scoring point 
SSDE ................... Sjogrens syndrome dry eye 
SSS ...................... surfactant stock solution 
TEM ..................... transmission electron microscopy 
TF ......................... tear film 
TFBUT ................. tear film break up time 
tHTP ..................... turbidimetric high throughput 
TNFα .................... tumor necrosis factor α 
UHPLC ................. ultra high pressure liquid chromatography 
VE ........................ viscosity enhancer 
VEGF ................... vascular endothelial growth factor 
ZAV ........................ hydrodynamic diameter 
π ........................... osmotic pressure 
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